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The most widely used animal model for biomedical research is the mouse. Yet, the physiolog-
ical differences between mice and humans sometimes result in findings of questionable trans-
lational value. The common marmoset monkey (Callithrix jacchus) is a non-human primate, 
which is gaining more and more interest as a translational model organism. However, meth-
ods for the genetic modification, which have been well-established in the mouse for decades, 
have only recently become available for the common marmoset.  
In this study I applied different tools for transgenesis and targeted gene modification using the 
common marmoset as a model organism. The initial part of the study was performed at the 
Central Institute for Experimental Animals in Kawasaki, Japan, where I was successful in 
generating two transgenic common marmoset monkeys using the Early Transposon promoter 
and Oct4 and Sox2 enhancers (EOS) lentiviral vector. The EOS vector mediates pluripotency-
associated expression of enhanced Green Fluorescent Protein (eGFP) and, once introduced as 
a transgene, can be utilized as a fluorescence marker of pluripotent cells. The other parts of 
my work were accomplished at the German Primate Center in Goettingen. To test EOS activi-
ty in the common marmoset, fibroblasts of the EOS transgenic monkeys were reprogrammed 
to induced pluripotent stem (iPS) cells by non-viral means using the piggyBac transposon 
system. Notably, I was able to reprogram primary fibroblasts making use of only the four 
classical reprogramming factors SOX2, OCT4, KLF4 and c-MYC, omitting LIN28, which 
was reported to be essential for common marmoset monkey cell reprogramming. In the end I 
used a recent approach for targeted gene modification, the CRISPR/Cas9 system, to modify 
the Parkinson’s disease associated gene LRRK2 in common marmoset primary fibroblasts. In 
addition to that, I generated immortalized common marmoset monkey fibroblast cell lines by 
stably introducing the human telomerase reverse transcriptase (hTERT) transgene again using 
the piggyBac transposon.  
In conclusion, I successfully applied different strategies for the genetic modification of genes 
in the common marmoset genome. My study will hopefully contribute to an expanded appli-
cation of the common marmoset in biomedical and translational research.  
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1. Introduction  
The following chapters will give an overview of the model organisms in biomedical research 
in general and the used common marmoset in detail. I will also give an overview of the main 
tools for genetic modification applicable in whole organisms or cells. Additionally, embryon-
ic stem (ES) cells and induced pluripotent stem (iPS) cells, both highly relevant cell types for 
biomedical applications and translational research, will be introduced. Finally, possible appli-
cations of these tools and techniques for genetic modifications in (cells of) the common mar-
moset monkey will be described.  
1.1 Model organisms in biomedical research 
During the history of biomedical research many model organisms contributed significantly to 
today’s biomedical knowledge. Among the most widely used organisms are the fruit fly Dro-
sophila melanogaster (Prüßing et al., 2013; Smith et al., 2014) the nematode Caenorhabditis 
elegans (Alexander et al., 2014), and the zebra fish danio rerio (Newman et al., 2014; Santo-
ro, 2014). The most commonly used mammalian models by far are rodents. Mainly the mouse 
model contributed essentially to today’s insight into developmental, physiological and molec-
ular processes in mammals. One of the reasons for that is the relative ease to alter the mouse 
genome. In 1976, the first transgenic mouse with integrated virus DNA and germline trans-
mission was reported (Jaenisch, 1976). In 1980 the first study about transgenesis by DNA 
microinjection into early mouse embryos was published (Gordon et al., 1980) and one year 
later also germline transmission of a microinjected transgene was reported (Gordon and Rud-
dle, 1981).Targeted gene modification, enabled by homologous recombination, in mouse em-
bryonic stem (ES) cells was first reported in 1989. Injection of these gene modified ES cells 
into mouse blastocysts resulted in chimeric mice, which were bred to obtain mice heterozy-
gous for the modified gene (Capecchi, 1989a; 1989b). The early development of these meth-
ods for transgenesis and targeted gene modification had an immense impact on biomedical 
research. However, due to the phylogenetic distance of the mouse and primates, biomedical 
research with the mouse as a model organism often reaches its limits regarding the genetical, 
developmental, behavioral, and physiological comparability to humans (Adams et al., 2003; 
Seok et al., 2013). These differences sometimes result in questionable translational value of 
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findings, e.g. in research regarding neurodegenerative diseases (Markou et al., 2009; Nestler 
and Hyman, 2010) or infectious diseases (Roep et al., 2012).  
1.1.1 Non-human primates in biomedical research  
Due to their relatively recent common ancestry, non-human primates (NHP) are more similar 
to humans than rodents. Therefore they represent excellent model organisms for translational 
research aiming at humans. The similarities in anatomy, morphology, reproduction, develop-
ment, cognition, social complexity and physiology between humans and NHP indicate the 
reasonability and validity of translational research with NHP as models (Phillips et al., 2014; 
Roep et al., 2012; Sasaki, 2015; t Hart et al., 2015). 
In the last decade(s) the interest in research with NHP increased and important findings and 
developments with NHP were made, including transgenesis in rhesus macaques (Chan et al., 
2001) and common marmosets (Sasaki et al., 2009) as well as directed gene-modification in 
rhesus and cynomolgus monkeys (Liu et al., 2014; Niu et al., 2014). This expanded set of ex-
perimental tools further promoted the attractiveness and possibly also the relevance of NHP 
models, especially in research areas like neuroscience, stem cell biology, and reproductive 
biology as well as for preclinical studies of novel therapeutic treatments. 
1.1.2 The common marmoset as a model organism  
Old World monkeys, primarily the rhesus macaque (Macaca mulatta) and the cynomolgus 
monkey (Macaca fascicularis), have been the main NHP models in biomedical research for 
decades. The reasons for that are mainly the evolutionary proximity to humans and the ease of 
access to these species. However, New World monkeys, especially the common marmoset 
(Callithrix jacchus), gain more and more interest in biomedical research. Among the ad-
vantages of the common marmoset over other NHP like the rhesus macaque, are the smaller 
size, the shorter generation time, and easier colony management (Mansfield, 2003; Ward and 
Vallender, 2012). Additionally, colony health can be sustained at a high level (Ludlage and 
Mansfield, 2003), and biosafety issues like herpes B virus infection in rhesus macaques, are 
no concern in the common marmoset (McCarthy and Tosolini, 1975). 
The common marmoset is a non-endangered species naturally living in northeastern Brazil. 
Common marmosets reach sexual maturity at the age of 1.5 to 2, give birth to approximately 3 
to 5 offspring a year and have a bodyweight of about 350 to 450g (Abbott et al., 2003; Tardif 
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et al., 2003). The large number of possible offspring (rhesus macaques have only one off-
spring a year), together with the early onset of sexual maturation, is a great advantage of the 
common marmoset for the establishment of transgenic colonies (Okano et al., 2012). 
Because marmosets are susceptible to a multitude of human diseases (Carrion and Patterson, 
2012), the common marmoset represents an ideal model for infectious disease research, drug 
development, and toxicology screening (Mansfield, 2003; Smith et al., 2001; t Hart et al., 
2015; Ward and Vallender, 2012). The common marmoset is a valuable and well-established 
model for specific purposes and already widely used in biomedical research (t Hart et al., 
2012). It has been used as a model in infectious disease research, e.g. for Epstein-Barr-virus 
(Felton et al., 1984), and hepatitis A virus (Pinto et al., 2002), in reproductive biology (Eil-
dermann et al., 2012; Lin et al., 2012), neuroscience (Ando et al., 2008; Jenner et al., 1984), 
or regenerative medicine (Bernemann et al., 2011; Kitamura et al., 2011; Pluchino et al., 
2009). Furthermore, common marmoset embryonic stem (ES) cells (Müller et al., 2009; Sasa-
ki et al., 2005) as well as induced pluripotent stem (iPS) cells (Debowski et al., 2015; Tomio-
ka et al., 2010; Wiedemann et al., 2012) have been derived. The development of basic re-
search resources and tools like whole genome sequencing (Worley et al., 2014), magnetic 
resonance imaging (MRI) techniques (Hikishima et al., 2011; Yamada et al., 2008), or the 
development of transgenesis in the common marmoset (Sasaki et al., 2009) further increases 
the value of the common marmoset as a biomedical model. All these achievements and char-
acteristics of the common marmoset make it an ideal model organism for biomedical research. 
However, in the common marmoset, applications that allow transgenesis and targeted gene 
modification have only recently been established. 
1.2 Tools for genetic modification  
Advancements in research led to improved and new methods that offer new possibilities for 
biomedical research. The next chapters will give an insight into gene modification methods 
also applicable in NHPs like the common marmoset.  
1.2.1 Lentiviral vectors 
Viral vectors in general can be used to transfer DNA into cells. Several different types of vi-
ruses, like retroviruses and adenoviruses, are used in research. The most known and used vi-
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ruses for gene delivery are retroviruses. Retroviruses can infect cells and integrate a transgene 
into a host cells’ genome through reverse transcriptase activity. 
A well-known family of retroviruses are lentiviruses. The main difference between standard 
retroviruses and lentiviruses is the inability of standard retroviruses to infect non-dividing 
cells, whereas lentiviruses can efficiently infect actively dividing and non-dividing cell types 
(Naldini et al., 1996; Vigna and Naldini, 2000).  
Lentiviral vectors have been derived from different types of lentiviruses including Human 
Immunodeficiency Virus Type 1 (HIV-1), Human Immunodeficiency Virus Type 2 (HIV-2) 
and Simian Immunodeficiency Virus (SIV). Characterized best are the HIV-1 based lentiviral 
vectors and are therefore mainly used in research. Lentiviral vectors are regarded to offer 
long-term stable expression of inserted transgenes in vitro and in vivo (Vigna and Naldini, 
2000). However, other reports indicate possible silencing of lentiviral vectors due to DNA 
methylation or histone modification (Antoniou et al., 2013; Ellis, 2005). 
1.2.2 The piggyBac transposon system 
A promising alternative to viral vector based gene transfer into cells are DNA transposons. 
Transposons are mobile DNA elements that can be utilized for gene integration into a host 
cell genome. The best-known and established transposon systems are the Sleeping Beauty and 
the piggyBac transposon system. 
The piggyBac transposon system is derived from the cabbage looper moth Trichoplusia ni and 
is a highly efficient transposon system for gene integration (Li et al., 2013; Wilson et al., 
2007). The piggyBac system consists of two components, a donor plasmid containing the 
DNA sequence of interest flanked by 5' and 3' terminal repeats, and a plasmid expressing the 
piggyBac transposase enzyme that catalyzes the integration. DNA integration into the host 
genome occurs at TTAA nucleotide sites (Bauser et al., 1999). 
The piggyBac system offers virus free integration into a target genome and shows stable ex-
pression of the integrated sequences. In contrast to all other known transposon-based systems, 
it is completely excisable not leaving any residual modifications or mutations in the host ge-
nome. This is of particular interest if only transient expression of a transgene and genomic 
integrity after terminated expression is required. DNA sequences of up to 14kb can be inte-
grated via piggyBac, which exceeds the sizes of lentiviral gene transfer (Kim and Pyykko, 
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2011). Furthermore, in contrast to lentiviral based gene integration, no transgene silencing in 
piggyBac was reported yet. 
1.2.3 CRISPR/Cas9 System 
A relatively new method for genome modification is the clustered, regularly interspaced, short 
palindromic repeat (CRISPR)/CRISPR associated nuclease 9 (Cas9) system. The 
CRISPR/Cas9 system facilitates easy and fast targeted gene modification in virtually all or-
ganisms and cell types. Previously, zinc finger nucleases (ZFNs) and transcription activator-
like effector nucleases (TALENs) have been developed as tools to modify mammalian ge-
nomes (Bibikova et al., 2001; Boch et al., 2009). The CRISPR system, however, has several 
advantages: i) overall it is faster, easier, and cheaper to use ii) for a new target it is sufficient 
to change a short DNA stretch without the need to change a whole construct / protein iii) it is 
possible to target multiple gene loci in one experiment (Cong et al., 2013; Hsu et al., 2014; 
Wang et al., 2013).  
CRISPR/Cas9 originally evolved as an adaptive defense mechanism in archea and bacteria for 
protection against invading virus or plasmid DNA (Wiedenheft et al., 2012). The system con-
sists of two RNAs, the CRISPR RNA (crRNA), and the trans-activating crRNA (tracrRNA). 
These two RNAs form a sequence-specific duplex that guides the Cas9 nuclease to an invad-
ing foreign DNA, which the nuclease can cleave to protect the host organism. The crRNA 
contains a sequence of 20 base pairs (bp) that is complementary to the invading DNA and is 
inserted into the host genome from a previous invasion event. The CRISPR system in bacteria 
and archaea contains multiple such foreign DNA stretches in the cells genomes and therefore, 
it can recognize and cleave different invading DNAs.  
The CRISPR/Cas9 system used as a tool in biology is derived from the bacteria Streptococcus 
pyogenes. It was shown that the mentioned crRNA and tracrRNA of Streptococcus pyogenes 
can be fused to form a single RNA sufficient for guiding the Cas9 to its target (Jinek et al., 
2012). The crRNA:tracrRNA combination is usually referred to as guideRNA (gRNA) (Cong 
et al., 2013; Jinek et al., 2012; Mali et al., 2013b) or single-guide RNA (sgRNA) (Platt et al., 
2014; Ran et al., 2013). The sequence-specific part of the gRNA can be easily exchanged to 
target virtually any DNA sequence. The Cas9 nuclease can cleave the double stranded (ds) 
DNA and induces a double-strand break (DSB) (Figure 1.1). DSBs are usually repaired by 
one of two cell repair mechanisms: i) non-homologous end joining (NHEJ) or ii) homology 
directed repair (HDR). Both mechanisms can be utilized to modify the target genome. With-
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out a repair template present cleaved dsDNA is religated by the NHEJ mechanism, which 
frequently is inaccurate and introduces mutations in the target region in form of insertions or 
deletions (indels). These indels can cause frameshift mutations and premature stop codons 
resulting in a functional gene knock out (Cong et al., 2013; Mali et al., 2013b; Ran et al., 
2013). Furthermore, multiple induced DSBs introduced in a larger target region can be used to 
generate extended deletions in the target genome (Cong et al., 2013). When a homologous 
repair template is provided together with the CRISPR/Cas9 components, HDR can be utilized 
to generate precise gene modifications. Possible applications include introduction of point 
mutations and insertion of a DNA sequence into the target genome. 
 
Figure 1.1: Overview of the RNA-guided Cas9 nuclease. The Cas9 nuclease from Streptococcus pyogenes is 
shown in yellow. Cas9 is guided to the genomic DNA (“DNA target”) by the guide RNA (“sgRNA”) consisting 
of a 20-nt guide sequence (marked in blue) and the sgRNA scaffold (marked in red). The 20-nt guide sequence 
pairs with the DNA target sequence (also called protospacer; blue bar), directly upstream of the essential 5′-NGG 
protospacer adjacent motif (PAM; pink bar). Cas9 introduces a DSB (red triangle) ~3 bp upstream of the PAM. 
(Modified from Ran et al. 2013) 
The only restrictions for the use of the CRISPR/Cas9 system are the following: i) the target 
region, also called protospacer (Figure 1.1), needs to be of the length of 20bp, and ii) the tar-
get/protospacer need to be directly followed by a protospacer adjacent motif (PAM) consist-
ing of NGG (Jinek et al., 2012) (Figure 1.1), where N stands for any nucleotide. This means 
that any sequence of the form 5' NNNNNNNNNNNNNNNNNNNNNGG 3' can be targeted. 
The PAM sequence is important for Cas9 nuclease target recognition (Jinek et al., 2012; 
Wiedenheft et al., 2012). However, the PAM is only present in the target sequence and not 
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included in the gRNA sequence. Possible target sites can be found approximately every 8-
12bp in the human genome and therefore targeted gene modification is possible at virtually 
any locus in the genome (Cong et al., 2013; Hsu et al., 2013; Ran et al., 2013). 
Targeted gene modification with the CRISPR/Cas9 system has already been reported for nu-
merous mammalian species including human (Jinek et al., 2013), mice (Wang et al., 2013), 
the cynomolgus monkey (Niu et al., 2014), and pig (Whitworth et al., 2014), but is also appli-
cable to non-mammalian species like the zebrafish (Hwang et al., 2013). Moreover, a recent 
controversially discussed publication reported the use of CRISPR/Cas9 in human embryos 
(Liang et al., 2015). 
A concern that needs to be addressed when working with the CRISPR system is the possibil-
ity of off-target effects (Fu et al., 2013; Pattanayak et al., 2013). Previous reports suggested 
that for proper target recognition the gRNA and target DNA need to be 100% complimentary 
in the PAM sequence and the 7-12 base pairs adjacent to the PAM (gRNA 3' end). Mismatch-
es at the 5' end of the gRNA, however, are tolerated and can lead to off-target effects (Cong et 
al., 2013; Jiang et al., 2013; Jinek et al., 2012). 
So far, no studies have been reported that show the functionality of CRISPR/Cas9 in the 
common marmoset.  
1.3 Pluripotent stem cells 
Pluripotent stem cells play an important role in biomedical research. They have a high poten-
tial with regard to disease modeling and are promising candidates for cell replacement thera-
pies.  
1.3.1 Embryonic stem (ES) cells  
In mammalian fertilization fusion of both the male and female gametes results in the for-
mation of the zygote. During early development the zygote undergoes several cleavage divi-
sions and gives rise to the blastocyst. The blastocyst consists of an outer single layer of cells, 
the trophoblast, and an inner accumulation of cells, called the inner cell mass (ICM) or em-
bryoblast. The ICM finally gives rise to the embryo proper. If cultured in vitro under appro-
priate conditions, the isolated ICM can give rise to embryonic stem (ES) cells.  
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The first ES cells were generated independently by two groups in 1981 (Evans and Kaufman, 
1981; Martin, 1981) from mouse embryos, the first human ES cells were generated in 1998 
(Thomson et al., 1998). ES cells from marmosets were first reported in 1996 (Thomson et al., 
1996) and later also others successfully generated marmoset ES cells (Müller et al., 2009; 
Sasaki et al., 2005). 
Embryonic stem cells have the potential to proliferate indefinitely in vitro and they are plu-
ripotent meaning that they can differentiate into any cell type of the three embryonic germ 
layers (ectoderm, mesoderm, endoderm). These characteristics made them interesting for 
studying early development and cell differentiation. Furthermore, ES cells have great poten-
tial for possible cell replacement therapies (Smith, 2001; Solter, 2006) of so called degenera-
tive diseases.  
In mouse genetically modified ES cells, when injected into embryos, eventually give rise to 
chimeric mice, which subsequently are bred and used as in vivo disease models.  
ES cells form colonies with a tightly packed morphology, are usually cultured on mouse em-
bryonic fibroblasts (MEFs) as feeder layers, and express several characteristic marker genes, 
e.g. OCT-4, TRA-1-60, SSEA-4 (Boiani and Schöler, 2005), indicative for the pluripotent, 
undifferentiated state of the cells; so called pluripotency markers. 
Due to their embryo origin, especially human ES cells are highly controversial in the public. 
New methods nowadays allow the generation of ES cell like cells from somatic cells, thereby 
circumventing the usage of embryos.  
1.3.2 Induced pluripotent stem (iPS) cells 
A revolutionary development for biomedical research was the “reprogramming” of somatic 
cells via ectopic expression of pluripotency-associated factors by Takahashi and Yamanaka in 
2006. 
Takahashi and Yamanaka screened 24 candidate genes that are highly expressed in ES cells 
for their potential to induce pluripotency in somatic cells. They found that four transcription 
factors, SOX2, OCT4, KLF4 and c-MYC (SOKM) are sufficient to reprogram murine fibro-
blasts into so-called induced pluripotent stem (iPS) cells. This method to generate pluripotent 
cells without the necessity of destroying embryos was later also successfully applied by sev-
eral others (Okita et al., 2007; Wernig et al., 2008). Other reprogramming factors, LIN28 and 
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NANOG, were sometimes used in exchange for KLF4 and/or c-MYC (Haase et al., 2009; Yu 
et al., 2009; 2007). Especially the exclusion of c-MYC is pursued (Wernig et al., 2008) as it is 
a proto-oncogene and enhances the tumorigenicity of  iPS cells (Okita et al., 2007).  
Induced PS cells show highly similar properties to ES cells: morphology, growth features, 
maintenance of pluripotency and expression of specific marker genes (Nakagawa et al., 2008; 
Okita et al., 2007; Takahashi and Yamanaka, 2006; Takahashi et al., 2007; Yu et al., 2007). 
Yet, iPS cells are not identical to ES cells, which is shown by the slightly different gene-
expression signatures and DNA methylation status (Chin et al., 2009; Kim et al., 2010; 
Takahashi and Yamanaka, 2006). Nonetheless, the possibility to generate iPS cells from hu-
man somatic cells offers great opportunities for research and clinical applications as cell re-
placement therapies (An et al., 2012; Shaer et al., 2014; Stern and Temple, 2011; Zeng and 
Couture, 2013). Induced PS cells can already be used for pharmacological studies and to gen-
erate disease models by derivation of disease-specific stem cells. For instance, research with 
iPS cells from Parkinson’s disease patients is ongoing (Loewenbrück and Storch, 2011; 
Soldner et al., 2009)  
The first iPS cells were generated by retroviral/lentiviral based gene integration of the repro-
gramming factors. Use of viruses limits the clinical application of iPS cells because of the 
high tumorigenicity of the iPS cells due to genome modification resulting from random pro-
viral genomic integration and ectopic expression of potential oncogenes. To obtain transgene 
free iPS cells, several alternatives to retroviral transduction can be applied. Reprogramming 
was also achieved employing adenoviral or episomal non-integrating vectors (Stadtfeld et al., 
2008; Yu et al., 2009) and integrating but excisable vectors like the cre-recombinase excisable 
virus (Soldner et al., 2009), or the piggyBac transposon system (Kaji et al., 2009; Woltjen et 
al., 2009). Moreover, DNA free reprogramming through consecutive transfection of recombi-
nant proteins (Kim et al., 2009) or in vitro transcribed mRNA (Plews et al., 2010; Tavernier et 
al., 2011; Warren et al., 2010; Yakubov et al., 2010) was realized. However, reprogramming 
using proteins circumventing any nucleic acid could not be repeated for far. Additionally, 
methods relying on repeated transfection of episomal vectors or recombinant proteins show 
very low reprogramming efficiencies (Kim et al., 2009; Yu et al., 2009).  
Induced PS cells were also generated from the common marmoset monkey (Debowski et al., 
2015; Tomioka et al., 2010; Wiedemann et al., 2012). However, iPS cell generation from 
common marmoset fibroblasts proofed to be more challenging as the derivation of iPS cells 
from mouse or human fibroblasts. Tomioka et al. reported that the four factors SOKM initial-
Introduction 19 
 
ly used for reprogramming were not sufficient for the reprogramming of common marmoset 
cells. The two additional reprogramming factors LIN28 and NANOG were shown to be nec-
essary for the generation of stably reprogrammed common marmoset iPS cells (Tomioka et 
al., 2010). However, some groups reported a successful reprogramming of marmoset somatic 
cells with just the classical four factors, but with a morphology less comparable to marmoset 
ES cells then in six factor reprogrammed iPS cells (Wiedemann et al., 2012; Wu et al., 2010). 
Research with iPS cells in the common marmoset allows modeling of diseases and offer ideal 
prerequisites for preclinical testing of cell replacement therapies. 
1.4 Possible applications for gene modification in the common 
marmoset 
1.4.1 EOS-EiP transgenic common marmosets  
A major obstacle in disease modeling in the common marmoset was the lack of protocols for 
the genetic modification of marmosets. In 2009, Sasaki et al. were the first to generate trans-
genic common marmosets. This study was at the same time the first that showed germline 
transmission of a transgene in NHPs. This achievement opened the possibility to mimic a sub-
set of human diseases in NHP. Such models would be of great value to study disease progres-
sion as well as efficacy of new therapeutic drugs. Furthermore, in validated disease models 
new treatment methods like cell replacement therapy and gene therapy can be tested (Chan 
and Yang, 2009; Sasaki et al., 2009). 
For the integration of a transgene Sasaki et al. used lenti-viral vector based gene delivery. 
Lenti-viral vectors proofed to be an ideal tool for transgenesis as shown for several different 
species like e.g. pigs and bovine (Hofmann et al., 2003), mice (Lois et al., 2002) and rhesus 
macaques (Yang et al., 2008). This efficient gene delivery method allows a minimal number 
of animals used for transgenesis experiments, thereby reducing ethical concerns associated 
with NHP research (Chan and Yang, 2009). 
Ideal for the generation of transgenic marmosets are one-cell stage embryos, generated via in 
vitro fertilization (IVF) (Tomioka et al., 2012). To obtain a high number of oocytes necessary 
for IVF, animals are superovulated by treatment with follicle stimulating hormone (FSH), as 
it increases oocyte generation (Marshall et al., 2003; Sasaki et al., 2009). Oocytes are then 
colleted from ovaries by aspiration with a needle and syringe. The one-cell stage embryos 
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obtained by IVF are subsequently injected with a virus to generate transgenic animals. The 
advantage of one-cell stage embryos in comparison to e.g. blastocyst stage embryos is a high-
er possibility for virus integration into all germ layers and therefore a lower possibility for a 
genetic mosaic in the developing offspring. For an efficient IVF several oocyte/embryo han-
dling techniques like in vitro maturation (IVM) and in vitro culture (IVC) are of great im-
portance (Tomioka et al., 2012). With the help of IVM collected, immature, not yet fertiliza-
tion competent oocytes can be matured for a highly efficient IVF. After IVF, IVC of the ferti-
lized oocyte (one cell-stage embryo) is used to assure efficient development of embryos for 
embryo transfer into surrogate mothers. The mentioned methods are basically essential for the 
generation of genetically modified common marmosets, which may represent an advanced 
biomedical research model. 
The establishment of a pluripotency reporter system in the common marmoset, already uti-
lized in mice and in human cell lines, would be highly beneficial for biomedical research.  
In human and mouse cells the Oct4-promoter driven expression of Green fluorescent protein 
(GFP) is widely used as a reporter for pluripotent cells (Boiani et al., 2002; Gerrard et al., 
2005; Szabó et al., 2002). The homozygous OG2 mouse strain is used for crossbreeding, for 
example with disease model strains, to obtain experimental mice heterozygous for Oct4-GFP 
(Boiani et al., 2002; Szabó et al., 2002). In 2009, Hotta et al. developed an alternative pluripo-
tency reporter to the Oct4-GFP reporter system: the Early Transposon promoter and Oct4 and 
Sox2 enhancers (EOS) lentiviral vector containing an enhanced GFP (eGFP)-IRES-Puror 
(EiP) cassette (Figure 1.2). 
 
Figure 1.2. EOS lentiviral vector. Ψ+: Enhanced packaging signal, RRE: Rev response element, Oct4 (red dia-
mond) and Sox2 (green triangle) binding sites inside the enhancer element, the Early Transposon promoter is 
located upstream of eGFP and indicated in red, IRES: Internal ribosomal entry site, Puror: Puromycin resistance, 
SIN: Self inactivating deletion. (Figure from Hotta et al., 2009) 
The EOS-EiP reporter mediates enhanced GFP (eGFP) expression through an Early Trans-
poson (ETn) promoter that showed high activity in mouse ES cells. To circumvent viral vec-
tor silencing and to achieve pluripotent cell specific expression OCT4 and SOX2 binding mo-
tifs from ES cell-specific enhancers were added (Figure 1.2). A major advantage of this sys-
tem is the possibility not only to visually identify pluripotent cells but also to select them us-
ing Puromycin (Hotta et al., 2009). In experiments aiming at the induction of pluripotency in 
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mouse and human fibroblasts, it was possible to enrich emerging reprogrammed cells for the 
isolation of iPS cell lines using this EOS-EiP reporter. Additionally, after differentiation of 
iPS cells, EOS-eGFP expression is extinguished again due to Oct4 and Sox2 silencing. Hence, 
with regard to a potential application of the cells, residual pluripotent and potentially teratoma 
forming cells are marked by eGFP expression. 
In summary, murine and human iPS cells can be monitored regarding their developmental 
state in real time. However, visualization of the differentiation status of common marmoset 
cells has not been achieved yet. 
1.4.2 Establishment of CRISPR/Cas9 on Parkinson’s disease related 
gene LRRK2 
Parkinson’s disease (PD), after Alzheimer’s disease, is the second most common progressive 
neurodegenerative disease. PD affects approximately 0.5 to 1% of the population at 65 years 
of age, increasing to 1 to 4% in the population over 80 years of age (Nussbaum and Ellis, 
2003). Furthermore, PD has an increasing prevalence due to the increasing life expectancy in 
todays societies (de Lau and Breteler, 2006).  
For a long time PD was regarded to be a solely sporadic disease caused by environmental 
factors until first studies showed possible hereditary causes linking mutations in the gene α-
synuclein to familial cases of PD (Polymeropoulos et al., 1996; 1997). Today it is known that 
approximately 90% of all PD cases are sporadic and 10% are hereditary (Thomas and Beal, 
2007). The identified genes involved in hereditary cases of PD include α-synuclein and leu-
cine-rich repeat kinase 2 (LRRK2) (Klein and Westenberger, 2012; Trinh and Farrer, 2013).  
An important way to better understand PD is the use of PD animal models. The most promis-
ing Parkinson models so far were induced with the chemical reagent 1-methyl-4-phenyl-
1,2,3,6-tetrahydropyridine (MPTP) (Forno et al., 1993) or with 6-OHDA (Schwarting and 
Huston, 1996). Especially in non human primates like common marmoset and rhesus ma-
caque these chemicals cause clinical symptoms highly similar to PD in humans (Porras et al., 
2012). These models contributed to a better understanding of PD and also helped to test new 
therapies for treating PD symptoms (Betarbet et al., 2002; Porras et al., 2012). However, Par-
kinson models based on MPTP can only model some acute clinical and pathological attributes 
of PD (Betarbet et al., 2002). Furthermore, these models fail to display the progressive nature 
of PD (Betarbet et al., 2002; Porras et al., 2012). 
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In contrast to the immediate induction of the PD symptoms in chemically induced models, 
genetic models (most likely will) show a development and progression of the disease symp-
toms better reflecting the clinical progression seen in patients. Different transgenic mouse 
models for PD were established by overexpressing human α-synuclein gene. These models 
display different PD symptoms like age dependent loss of dopaminergic neurons (Betarbet et 
al., 2002; Janezic et al., 2013; Masliah et al., 2000; Porras et al., 2012) motor deficits (Janezic 
et al., 2013; Masliah et al., 2000; van der Putten et al., 2000) and α-synuclein positive inclu-
sions (Masliah et al., 2000; van der Putten et al., 2000). However, the short life span of mice 
limits the investigation of the progressive features of PD. In addition, brain development and 
behavior are not entirely comparable to humans resulting in a relatively low translational val-
ue of findings made in mice (Belmonte et al., 2015; Phillips et al., 2014). Another possible 
target for transgenic animal models is the LRRK2 gene. Mutations in LRRK2 account for 4% 
of hereditary cases of PD and 1% of sporadic cases of PD which make them the most com-
mon genetic cause for PD (Healy et al., 2008; Kett and Dauer, 2012). The most common of 
the LRRK2 mutations is the Gly2019Ser mutation.  
In recent years several groups reported LRRK2 Gly2019Ser transgenic and knockin mice (Li 
et al., 2010; Lin et al., 2009; Melrose et al., 2010; Ramonet et al., 2011). However, these mice 
models only show a limited number of PD symptoms. 
A LRRK2 Gly2019Ser primate model is highly desired because it might exhibit more similar 
symptoms to humans. It could help to better understand the progressive nature of PD on the 
organismic level in a close relative of humans. Moreover, a LRRK2 transgenic NHP would 
allow the testing of new experimental treatments of PD. Especially the similarities between 
humans and common marmosets in social behavior and brain development make common 
marmosets an ideal model organism for studying PD (Dell'Mour et al., 2009; Okano et al., 
2012).  
1.4.3 Generation of immortalized common marmoset fibroblast cells 
Human somatic cells, like fibroblasts, can only undergo a limited number of cell divisions in 
vitro before they enter a state of growth arrest termed “senescence” (Hayflick, 1965). Cells in 
senescence by definition cannot further divide. In contrast, cancer cells were found to be able 
to circumvent senescence and to continue proliferation in cell culture beyond their normal 
lifespan (Mathon and Lloyd, 2001). However, after some additional cell divisions cancer cells 
still proliferate, but also display high rates of apoptosis, a state that is named “crisis”. Crisis 
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results from major abnormalities in chromosomal structure (chromosomal shortening) (Ma-
thon and Lloyd, 2001). However, some cells are able to also circumvent crisis; these cells are 
immortal.  
The mechanism behind senescence and crisis were found to be based on telomere shortening 
(Wright and Shay, 1992). Telomeres are the ends of the chromosomes that are shortened with 
every cell cycle (Harley et al., 1990). When the telomeres reach a critical length, cells enter 
senescence (Wright and Shay, 1992). By inactivation of tumor suppressor genes like p53 and 
retinoblastoma (RB), cells can overcome senescence (Mathon and Lloyd, 2001). However, the 
telomeres continue to shorten and result in chromosomal instability that causes crisis. The 
enzyme telomerase is a ribonucleoprotein enzyme that elongates telomeres and its activity 
allows cells to overcome crisis and become immortal. Telomerase consist of two subunits, a 
template RNA and the catalytic protein telomerase reverse transcriptase (TERT), which uses 
the RNA template to elongate the telomere DNA (Kilian et al., 1997; Meyerson et al., 1997). 
The template RNA was found to be expressed in all tissues irrespective of telomerase activity 
(Avilion et al., 1996). In contrast, TERT is inactive in most somatic cells, but active in the 
germline, pluripotent stem cells, some types of adult stem cells, cancer cells and in vitro im-
mortalized cells. Therefore, TERT is regarded as the determinant of telomerase enzyme activi-
ty (Meyerson et al., 1997; Nakamura et al., 1997). 
Different studies showed that exogenous expression of human TERT (hTERT) alone was suf-
ficient to immortalize cells of several species. Human TERT-based immortalization was, 
among others, reported for different human cell types (Böcker et al., 2008; Darimont et al., 
2003; Salmon et al., 2000), sheep fibroblasts (Cui et al., 2002), different canine cells 
(Techangamsuwan et al., 2009), several types of porcine cells (Oh et al., 2007), and for rhesus 
macaque mesenchymal stem cells (Gao et al., 2008). Even though multiple groups reported a 
normal phenotype for their immortalized cells, other groups showed that hTERT immortalized 
cells can exhibit cancer-associated changes and neoplastic transformation (Belgiovine et al., 
2008; Harley, 2002; Mondello et al., 2003; Zongaro et al., 2005). Immortalization of common 
marmoset cells with hTERT is not reported yet. Such cells would be especially helpful for 
preliminary experiments before testing/experiments in vivo are carried out. 
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1.5 Aim of this study 
The aim of this study was to increase the available application possibilities of the common 
marmoset as a model organism in biomedical research. Therefore, it was planed to generate 
transgenic common marmosets carrying the pluripotency specific EOS-EiP marker to obtain a 
pluripotency reporter system in the common marmoset. Additionally, the CRISPR/Cas9 sys-
tem for targeted gene modification should be established in the common marmoset. As a first 
target for CRISPR/Cas9 based gene modification, the LRRK2 Gly2019Ser mutation of the 
LRRK2 gene was chosen, which is involved in hereditary and sporadic cases of PD. Further-
more, it was planned to generate immortalized common marmoset fibroblasts to obtain cells 
that can proliferate indefinitely in culture and would be helpful for e.g. preliminary in vitro 
experiments before in vivo experiments are considered. 
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2. Materials & Methods 
In this study, chemicals of AppliChem (Darmstadt), Amersham Pharmacia Biotech (Frei-
burg), Biozym (Hessisch Oldendorf), Fluka (Neu-Ulm), Merck (Darmstadt) and Sigma-
Aldrich (Deisenhofen) were used. Enzymes and appropriate buffers were obtained from Ap-
plied Biosystems/Ambion (Darmstadt), New England Biolabs (Frankfurt am Main) and 
Roche (Mannheim). For culturing and amplification of bacteria, media from Sigma-Aldrich 
(Deisenhofen) were used. Materials for cell culture and cell transfection were obtained from 
Bio Whittaker (USA), Gibco (Berlin), Invitrogen (Karlsruhe), Promega (Mannheim), Applied 
Biosystems/Ambion (Darmstadt) and Mirus Bio (Madison, USA). Antibiotics were used from 
Biochrom (Berlin) and Roche (Mannheim). All solutions were prepared in bi-distilled water 
(ddH2O) or in DEPC treated ddH2O. If necessary, solutions were sterilized by autoclaving (20 
min; 121 °C). Several methods were used from: Tobias Kahland, Diploma Thesis ”Establish-
ing methods for reprogramming differentiated cells from the Common Marmoset monkey 
(Callithrix jacchus) using modified mRNA” (2011). 
 
2.1 Laboratory Equipment 
 
Equipment Manufacturer 
Automated Enzyme ImmunoassayAnalyzer AIA-
900 
Tosoh, Tokyo, Japan 
Axio Observer Z1 Carl Zeiss, Oberkochen, Germany 
Biometra® T3000 Thermocycler Labrepco, Horsham, USA 
Drying Oven, MOV-112 Sanyo, Moriguchi, Japan 
Eppendorf Centrifuge Eppendorf AG, Hamburg, Germany 
Femto Jet Express  Eppendorf AG, Hamburg, Germany 
Gel iX Imager Intas, Göttingen 
HeatingBlockThermostat, TH 21 BioTech, Bergheim, Austria 
Heraeus incubator Thermo Scientific, Waltham, USA 
Horizon® 58 Gel Electrophoresis Apparatus LABRepCo, Horsham, England 
IKA®RCT basic safety control, #3810000 IKA, Staufen, Germnay 
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2.2 Polymerase chain reaction (PCR) 
2.2.1 PCR conditions 
 
PCR-Reactions were carried out with KOD Hot Start Polymerase (Merck, Darmstadt) in a 
T3000 Thermo Cycler from Biometra (Goettingen). The used program was as follows:          
   
 
 
For sufficient amplification, 30-40 cycles were performed. 
Each PCR reaction (50 µl) contained: 
 
∼50 ng (Plasmid) DNA or 50-100 ng genomic 
DNA  
3 µl of each 5 µM Primer 
5 µl 10 x Buffer for KOD Hot Start Polymerase 
LSRII cytometer  BD Biosciences, East Rutherford, USA 
Microcentrifuge Heraeus Fresco 21, #75002425 Thermo Scientific, Waltham, USA 
Multifuge Heraeus, 1 S-R Thermo Scientific, Waltham, USA 
Mupid®-ex electrophoresis system Mupid Co, Tokyo, Japan 
NanoPhotometer TM UV/Vis Spectrophotometer Implen, München, Germany 
Narishige micromanipulator Narishige, Tokyo, Japan 
4D-Nucleofector™ System 
Core unit AAF-1002B  
X unit, AAF-1002X 
Lonza, Basel, Switzerland 
PowerEase™500 Power Supply, #EI8700 Invitrogen, Karlsruhe, Germany 
Thermomixer® comfort Eppendorf AG, Hamburg, Germany 
Water Jacket Multi Gas Incubator Astec Co. Ltd., Fukuoka, Japan 
Table 2.1: PCR program for KOD Hot Polymerase. (Taken from KOD Hot Start Polymerase Manu-
al) 
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5 µl 2 mM dNTPs 
3 µl 25 mM MgSO4 
1 µl KOD Hot Start Polymerase 
X µl ddH2O  
 
The melting temperatures (Tm) of the primers were calculated by the following equation: 
Tm = (G/C) x 4°C + (A/T) x 2°C - (Base-mismatches) x 4°C - 4°C 
All used primer pairs are listed in 6.1. 
 
2.3 Escheria coli (E. coli) cell culture 
2.3.1 Used E. coli strain 
The NEB 10-beta Competent E.coli (High Efficiency) cell strain was used for DNA amplifi-
cation. The strain genotypes was:  Δ(ara-leu) 7697 araD139  fhuA ΔlacX74 galK16 galE15 
e14-  ϕ80dlacZΔM15  recA1 relA1 endA1 nupG  rpsL (StrR) rph spoT1 Δ(mrr-hsdRMS-
mcrBC) (NEB). 
 
2.3.2 Culture medium for E.coli 
 
LB medium was prepared by suspending 20 g of LB Broth (Sigma-Aldrich; #L3022) in 1 l of 
distilled water. To prepare LB-agar-plates, 35 g of “ready-to-use” LB agar (Sigma-Aldrich; 
#L2897) were suspended in 1 l of distilled water. Both the medium and the medium-agar sus-
pension were autoclaved for 15 min at 121 °C. The autoclaved medium was stored at room 
temperature and incubated for 30 min at 37 °C prior to usage. 
The liquified-agar-medium was cooled to roughly 50 °C. Ampicillin (final concentration: 
100 μg/ml) was added before plating the agar-medium into sterile petri-dishes.  
 
LB (Lysogeny-Broth)-Medium:  
1% (w/v) Tryptone 
0.5% (w/v) Yeast extract 
0.5% (w/v) NaCI 
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2.3.3 Transformation of NEB10-beta competent E. coli 
NEB10-beta (NEB) competent E. coli cells were thawed on ice for 10 minutes. 2 μL of the 
ligation reaction or 0.2µl of plasmid DNA was added, mixed carefully and incubated on ice 
for 30 min. The cells were heat-shocked at 42 °C for 30 sec, followed by incubation on ice for 
5 min. Each transformation was diluted in 950 μL SOC-medium and incubated for 1 h, at 37 
°C at 300 rpm. Afterwards, the cells were plated on a prewarmed selective agar plate contain-
ing 100μg/mL ampicillin for selection of transformed bacteria. The plates were incubated at 
37 °C for 15-17h.  
 
Super Optimal Broth with Catabolite repression (SOC) Medium: 
0.4% (w/v) Tryptone 
0.5% (w/v) Yeast extract 
15 mM NaCl 
2.5 mM KCl 
10 mM MgCl2 
10 mM MgSO4 
20 mM Glucose 
 
2.4 Cloning of DNA fragments  
 
In this study the following plasmid vectors were used: 
Cloning vector 
pcDNA3.1(-) 
Lentiviral packaging plasmids 
pCAG-HIVgp 
pCMV-VSV-G-RSV-Rev 
Both lentiviral packaging plasmids were obtained from RIKEN BioResource Center DNA 
Bank (RIKEN, Japan). 
Lentiviral pluripotency reporter plasmid: 
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PL-SIN-EOS-C(3+)-EiP 










The plasmid pBABE-neo-hTERT was a gift from Bob Weinberg (Addgene plasmid # 1774). 
pTT-PB-hTERT-puro 
CRISPR/Cas9 plasmids 
pSpCas9(BB)-2A-Puro (PX459)  
The plasmid PX459 was a gift from Feng Zhang (Addgene plasmid # 48139). 
 
All Addgene plasmids are available at: http://www.addgene.org/ 
2.4.1 DNA restriction digestion with endonucleases 
For restriction digest of DNA, restriction endonucleases (NEB) were used at a concentration 
of 5-10 U enzyme/µg plasmid DNA. The reaction was performed in 1 x incubation buffer 
(NEBuffer 1-4) and 1 x BSA, at 37 °C. In case of identical buffer requirements of the en-
zymes, incubation with several enzymes was performed simultaneously. Otherwise, buffer 
conditions were set in between the different incubations by adding appropriate salts. Re-
striction enzymes are stored in 50% glycerol, which has an inhibitory effect on enzyme activi-
ty. Therefore the amount of enzyme in a reaction should not exceed 10% of the total reaction 
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volume. Restriction analysis was performed in a total volume of 20 μl. Plasmid vectors were 
digested for at least 4 h. Otherwise, the reaction was incubated for 2 h followed by heat inac-
tivation of the restriction endonucleases at 65 °C for 20 minutes. 
2.4.2 Phosphatase treatment of linearized vector  
Antarctic Phosphatase (NEB, #M0289S) was used to catalyze the removal of 5' phosphate 
groups of digested DNA plasmids to prevent re-circularization. De-phosphorylation was per-
formed using ~2 μg digested vector DNA, 1/10 of the volume of Antarctic Phosphatase sup-
plemented with 10 x Antarctic Phosphatase Reaction Buffer (NEB, #B0289S) to a final con-
centration of 1 x. The reaction was incubated for 1 h at 37 °C. The enzyme was heat inactivat-
ed at 65 °C for 20 min.  
 
1 x Antarctic Phosphatase Reaction Buffer (pH 6,0): 
50 mM  Bis-Tris-Propane-HCl  
1 mM  MgCl2 
0.1 mM   ZnCl2 
  
 
2.4.3 Plasmid-safe treatment 
To remove residual single stranded DNA from ligation reactions, ligations were treated with 
Plasmid-Safe™ ATP-Dependent DNase (Epicentre). Therefore 0.3 µl Plasmid-Safe™ ATP-
Dependent DNase (Epicentre), 1.7 µl Plasmid-Safe 10x Reaction Buffer, 1.5 µl ATP (10 mM) 
and 3.5 µl ddH2O were added to a 10 µl ligation reaction mixture and incubated for 30 
minutes at 37 °C.  
2.4.4 Ligation 
For general ligation, up to 1 µg of insert DNA and ~50 ng of digested and de-phosphorylated 
vector DNA were incubated with 1 U T4 DNA ligase (Roche) in 1 x ligation buffer (Roche). 
1 µl of 25 mM MgCl2 was added to the mixture. The final volume was set to 10 µl. Ligation 
reactions were incubated at room temperature for at least 1 h. T4 DNA ligase was heat inacti-
vated at 65°C for 20 min.  
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1x T4 DNA Ligase Buffer 
50 mM Tris-HCl 
10 mM MgCl2 
1 mM ATP 
10 mM Dithiothreitol 
pH 7.5 at 25°C 
  
2.4.5 Generation of the pTT-PB-hTERT-puro plasmid for cell 
immortlization 
The pBABE-neo-hTERT plasmid was a gift from Bob Weinberg (Addgene plasmid # 1774) 
and was the source of the hTERT cDNA. The pTT-PB-SOKMLN-puro plasmid (Debowski et 
al., 2015) was provided by Katharina Debowski and was used as the backbone for piggyBac 
based transposition activity. pBABE-neo-hTERT and pTT-PB-SOKMLN-puro were both 
digested with EcoRI (NEB) and SalI (NEB) as described in 2.4.1. Both fragments of interest 
were segregated on an agarose gel (2.7.1) and extracted from the gel as described in 2.7.2. 
The hTERT cDNA was ligated into the pTT-PB-puro (without SOKMLN) backbone as de-
scribed in 2.4.4. The resulting plasmid pTT-PB-hTERT-puro was transformed into NEB10-
beta competent E.coli cells (2.3.3).  Afterwards, DNA was isolated using Maxi preparation 
(2.5.2). 
2.5 Plasmid DNA preparation from E. coli cells 
2.5.1  Mini preparations of plasmid DNA 
For small-scale plasmid isolation, 5ml LB medium were inoculated with a single colony and 
incubated over night at 37°C and permanent shaking. The plasmid DNA was isolated with the 
Qiaprep Spin Miniprep Kit (Qiagen), or the NucleoSpin Plasmid Kit (MACHEREY-
NAGEL). Both kits were used according to manufacturer’s instructions.  
2.5.2 Maxi preparation of plasmid DNA   
For large-scale plasmid isolation, 100ml LB medium were inoculated with a single colony 
and incubated over night at 37°C and permanent shaking. DNA plasmid Maxi preparations 
were carried out with the Qiagen Plasmid Maxi Kit (Qiagen) according to manufacturer’s 
instructions for high copy plasmids.  
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2.6 Isolation of genomic DNA 
Genomic DNA (gDNA) was isolated with the DNeasy Blood and Tissue Kit (Qiagen) accord-
ing to manufacturer’s instructions. For gDNA isolation, either fresh cells, or cells stored 
at -150 °C were used. 
2.7 Nucleic acid fragment segregation  
2.7.1 Agarose gel electrophoresis  
For analytical and preparative purposes, nucleic acids can be separated according to their size 
with the help of agarose gel electrophoresis. Large fragments in the range of 500-10.000 bp 
were separated in 0.75-1% (w/v) agarose gels. For separation of small DNA fragments, the 
agarose concentration was increased (1.5-2% (w/v)). The agarose was boiled in 1 x TAE 
buffer (Roth) until it was completely dissolved. After cooling to 60 °C, ethidium bromide was 
added to a final concentration of 1 µg/ml. The gel was poured into a gel tray and an appropri-
ate comb was inserted. DNA samples were prepared by adding 1/6 volume of 6 x loading dye 
(Fermentas, # R0611), then loaded onto the gel. As a size standard the GeneRuler™ 1 kb Plus 
DNA Ladder (Fermentas, #SM1343) was used. Electrophoresis was performed in 1 x TAE 
buffer (Roth) at either 200V for 25 min in a Horizon® 58 Horizontal gel electrophoresis appa-
ratus or at 135 V for 45 min in a Mupid®-ex electrophoresis system. DNA bands were visual-
ized under UV light (302 nm). 
 
TAE (50 x): 
2 M  Tris/Acetat pH 7.5 
50 mM EDTA  
2.7.2 DNA fragment extraction from agarose gels  
To obtain clean DNA from agarose gels, DNA bands were cut out of the agarose gel and were 
extracted with the Qiaquick gel extraction kit (Qiagen), or the Nucleospin Gel and PCR clean 
up kit (MACHEREY-NAGEL). Both kits were used according to manufacturer’s instructions.  
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2.8 Photometric quantification of nucleic acids 
Photometric quantification of nucleic acids was carried out with the Nano Photometer Pearl 
(IMPLEN, München) according to the manufacturer’s instructions. 
2.9 cDNA generation  
For cDNA generation first RNA was isolated from cells, either with the NucleoSpin® RNA 
Plus Kit (MACHEREY-NAGEL), or the RNeasy Mini Kit (Qiagen). Both kits were used ac-
cording to manufacturer’s instructions. To generate cDNA from isolated RNA, the Omniscript 
RT Kit (Qiagen, #205113) was used according to manufacturer’s instructions. For the reverse 
transcriptase (RT) reaction 1-2µg of RNA was used. For control purposes,  –RT reactions 
were performed. 
2.10 Real-time quantitative PCR 
For real-time quantitative-PCR (qPCR) cDNA was generated as described in 2.9. Real-time 
qPCR was performed on the StepOnePlus System (Applied Biosystems). For each qPCR re-
action, 10ng of template cDNA was mixed with Power SYBR PCR master mix (Applied Bio-
systems) and primers with a final concentration of 600 nM. All qPCR reactions were meas-
ured in technical triplicates to assure accuracy. The obtained data were normalized against the 
housekeeping gene 18S rRNA. All data are shown as means with the standard error of meas-
urement. All used primers are listed in 6.1. 
2.11 DNA Sequencing 
To verify nucleotide sequences, sequencing of purified PCR products or plasmid DNA was 
carried out by LGC Genomics (https://shop.lgcgenomics.com/). For sequencing of plasmid 
DNA, 4 μl primer (5 pMol/μl) were added to 10 µl template DNA at a concentration of 100 
ng/μl. Sequence analysis was performed with the programs 4 Peaks 
(http://nucleobytes.com/index.php/4peaks) and Serial Cloner 2.6 
(http://serialbasics.free.fr/Serial_Cloner.html). All used primer pairs are listed in 6.1. 
 
Materials & Methods 34 
 
2.12 Animal procedures and related techniques 
All mentioned methods under animal procedures were performed at the Central Institute for 
Experimental Animals (CIEA, Kawasaki, Japan). The methods describe the generation of 
transgenic common marmosets, starting with the collection of oocytes, over generation of in 
vitro fertilized one-cell stage embryos, to the embryo transfer into surrogate mothers. 
2.12.1 Animals and animal housing 
The common marmoset monkeys (Callithrix jacchus) used at the CIEA were obtained from 
the commercial breeder CLEA Japan, Inc. (Tokyo, Japan) or were bred at the CIEA. 
The animals were pair-housed in vertically orientated stainless steel cages with a size of 158 
cm x 40 cm x 61cm containing wooden branches and shelves for environmental enrichment. 
The facility temperature was 24-27°C with a relative air humidity of 40-60%. Illumination 
was provided through artificial lighting on a 12:12 hour light:dark cycle. The animals were 
fed ad libitum with foamed pellets CMS-1M (CLEA Japan Inc., Tokyo, Japan) specially de-
signed for marmoset diet, supplemented with L (+)-ascorbic acid (Nacali Tesque, Tokyo, Ja-
pan), vitamins A, D3 and E (Duphasol AE3D; Kyoritsu Seiyaku Co., Ltd., Tokyo, Japan) and 
honey (Nihonhatimitsu Co., Ltd., Gifu, Japan). Additionally, chicken liver (DBF Pet, Niigata, 
Japan) boiled in water was fed once a week as supporting nutrition. Drinking water was avail-
able ad libitum from feed valves. Health and wellbeing of the animals were controlled daily 
by vetenerians and animal care attendants.  
All animal experiments were approved by the Institutional Animal Care and Use Committee 
of the Central Institute for Experimental Animals (CIEA) (CIEA approval no: 11028, 14029) 
and were performed in accordance with the Basic Policies on Animal Experiments conducted 
in Research Institutions (Notice No. 71 of the Ministry of Education, Culture, Sports, Science 
and Technology of Japan, June 2006) and the Guidelines for Proper Conduct of Animal Ex-
periments by the Science Council of Japan (2006). The laboratory animal facility of CIEA has 
been certificated based on the assessment by the Center for Accreditation of Laboratory Ani-
mal Care and Use, Japan Health Sciences Foundation (Certification number: 12-025).  
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2.12.2 Progesterone measurement 
In order to determine the female stage of the reproductive cycle the plasma progesterone lev-
els were measured. Progesterone levels were checked by ELISA, using the Automated En-
zyme ImmunoassayAnalyzer AIA-900 (Tosoh, Tokyo, Japan) with the enzyme immunoassay 
(EIA) kit (Tosoh Progesterone Kit; Tosoh, Tokyo, Japan). The kit was used according to 
manufacturer’s instructions. The day of ovulation was defined as the day before the proges-
terone level exceeded 10 ng/ml. 
2.12.3 Ovarian cycle synchronization and superovulation 
 
To increase oocyte production, common marmoset females where treated with hormones as 
following. The hormone treatment was performed by veterinarians at the CIEA. For this study 
sixteen female adult common marmosets were used as oocyte donors. 
To determine the time-point of the ovarian cycle, blood samples were taken from adult female 
common marmosets to measure the progesterone level (2.12.2). To synchronize the ovulation 
cycles of donor and recipient females the animals where injected intramuscular with 0,75µg 
prostaglandin (PG) F2α analog cloprostenol (Estrumate; Schering-Plough Animal Health, 
Union, USA) during their luteal phase (10 days after ovulation). This was performed to in-
duce luteolysis and subsequently a new ovarian cycle. On day 1 after PGF2α injection anoth-
er progesterone measurement was performed to verify the start of a new ovarian cycle. To 
achieve superovulation, the intramuscular injection of recombinant human follicle stimulating 
hormone (rhFSH) (FOLYRMON-P; Fuji Pharma, Tokyo, Japan) with the dosage of 
25IU/day/animal was started (day 1). The FSH injection, once every morning, was continued 
until day 9. On day 10 at 17:00 75IU/animal of human chorionic gonadotropin (hCG) (Gonat-
ropin; ASKA Pharmaceutical, Tokyo, Japan) were injected. On day 11 the oocyte pick-up 
(OPU) (2.12.5) was started at 14:00. 
2.12.4 Anesthesia 
The anesthesia was performed by vetenerians of the CIEA. 
For induction of anesthesia, animals were injected with 0,04 mg/kg medetomidine (Dormitor; 
Nippon Zenyaku Kogyo, Koriyama, Japan), 0,40 mg/kg midazolam (Dormicam 10mg; Astel-
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las Pharma, Tokyo, Japan) and 0,40 mg/kg butophanol (Vetorphale; Meiji Seika Pharma, To-
kyo, Japan). During operation anesthesia was maintained via inhalation of 1,0-3,0% isoflurane 
(Forane; Abbott Japan, Tokyo, Japan) through a ventilation mask. During operation heart rate 
and arterial oxygen saturation was monitored. After the operation the animals were injected 
with 0,20 mg/kg atipamezole hydrochloride (Antisedan, Nippon Zenyaku Kogyo) for better 
recovery from anesthesia. 
2.12.5 Oocyte pick-up (OPU) 
For OPU surgery, the animals were anesthesized as described in 2.12.4. The animal abdomen 
was opened and the ovaries were pulled out of the abdominal cavity while still connected to 
the body by their oviduct and connective tissue (Figure 2.1 A). The follicles in the ovaries 
were punctured with a 25G needle connected to a 2.5 ml sized syringe and oocytes were col-
lected through aspiration (Figure 2.1 A). The Oocytes were collected in Porcine Oocyte Me-
dium (POM, Research Institute for the Functional Peptides, Yamagata, Japan). After the oper-
ation the ovaries were placed back into the abdomen and the wound was stitched. The opera-
tion was performed under sterile conditions. 
Records of each animal, including photograph of the appearance of the ovaries, number of 
oocytes and duration of operation were documented during OPU. 
 
Figure 2.1. A) Aspiration of oocytes from ovaries of FSH stimulated animals. Ovaries were carefully “pulled 
out” of the abdomen and the oocytes were aspirated with a needle and syringe. Arrow indicates punctured ovary 
B)-E) Overview of different developmental stages of oocytes derived from FSH stimulated animals. B-C) Ex-
ample of different possible appearances of Germinal vesicle (Gv) stage oocytes. B) Gv stage oocyte covered 
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with cumulus cells C) Gv stage oocyte without cumulus cells. D) Metaphase I stage (MI). E) Metaphase II stage 
(MII), arrow indicates polar body. Bars= ca. 50µm 
 
2.12.6 Oocyte sorting and in vitro maturation (IVM) 
After OPU, the oocytes were washed in supplemented POM and sorted by maturation stage. 
The different maturation stages were: 
Germinal vesicle stage (Gv) 
Metaphase I stage (M I) 
Metaphase II stage (M II) 
 
The different stages are described and shown in Figure 2.1 B-E. The MII stage Oocytes were 
directly used for in vitro fertilization (IVF) (2.12.7). The rest of the sorted Oocytes were 
placed in equilibrate drops of 80-100µl supplemented POM medium under mineral oil 
(Nacalai Tesque, Tokyo, Japan). They were incubated for in vitro maturation (IVM) at 38 °C, 
5% O2, 5% CO2 for ∼24 h. After IVM the Oocytes were sorted again. MII and MI stage Oo-
cytes were used for IVF.   
Supplemented POM:  
POM 
150 mIU/ml rhFSH, 
20 IU/ml hCG 
5% FBS 
2.12.7 Sperm collection, purification and in vitro fertilization (IVF) 
Fertilization competent sperm were needed to successfully fertilize oocytes. For this study a 
total number of seven adult male common marmosets were used. To collect sperm, common 
marmosets were stimulated until ejaculation with a FertiCare personal vibrator (Fertility 
Healthcare and Supplies, Silverado, USA). The ejaculated sperm were transferred to 500µl 
TYH media (LSI Medience Corporation, Tokyo, Japan). Afterwards, the sperm was centri-
fuged for 5 min at 400xg. The supernatant was discarded and the sperm pellet was resuspend-
ed in 500µl TYH. The sperm-TYH solution was incubated at 38°C, 5% CO2, 5% O2 for 30 
minutes. After incubation the sperm was centrifuged for 5min at 400xg. The supernatant was 
discarded and the sperm pellet was resuspended in 100µl TYH. The resuspended sperm was 
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transferred to the bottom of a conical tube containing 600µl TYH. The tube was incubated, 
while laying at a 30° angle, for 15-45 min at 38°C, 5% CO2, 5% O2. Afterwards, the upper 
400µl, containing the so-called “swim up sperm”, were collected. 6µl of the “swim up sperm” 
were used for sperm mobility analysis with the Sperm Mobility Analysis System (SMAS) 
(Ditect, Tokyo, Japan) to determine sperm concentration. 80-100µl drops of TYH containing 
3.6 - 4 x106 Sperm/ml were prepared. For IVF, oocytes (2.12.6) were transferred into the 
drops containing the sperm and were incubated for 15-17h at 38°C, 5%  CO2, 5% O2. 
2.12.8 Pronuclei formation check 
After 15-17h of incubation, the in vitro fertilized embryos were washed in ISM1 (Origio, 
Måløv, Denmark) to remove the sperm attached to the embryos. Next, the embryos were 
checked for the formation of the two pronuclei (2PN) to verify proper fertilization. Not 
properly fertilized embryos were discarded. In Figure 2.2 A-B an overview of possible ap-
pearances of embryos after fertilization is shown.  
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Figure 2.2. A) One-cell stage Embryo with 2PN, 17h post IVF (PN: Pronucleus  NPB: Nucleolar Precursor 
Bodies   ZP: Zona Pellucida). B) One-cell stage Embryo with 3PN, 17h post IVF. C) One-cell stage embryo in 
0.25M Sucrose with enlarged perivitelline space (PS), right before virus injection into the PS. 
2.12.9 Virus injection and in vitro culture (IVC) 
Virus injections were performed on days 1 after IVF with the Femto Jet Express (Eppendorf) 
and a Narishige micromanipulator (Narishige, Tokyo, Japan) in drops of 0.25M sucrose in 
PB1 (LSI Medience Corporation). 0.25M sucrose in PB1 was used to extend the perivitelline 
space for easier virus injection. Drops of 8-10µl 0.25M sucrose in PB1 were prepared and 
covered with mineral oil. 2PN embryos were transferred to the drops for virus injection. After 
virus injection, the embryos were first washed in PB1 (3-4 times) and afterwards transferred 
back to drops of ISM1 medium for in vitro culture (IVC). IVC was performed at 38°C, 5% 
CO2, 5% O2. On day 4 after IVF, the Medium was changed to BlastAssist Medium (Origio), 
which shows better properties for blastocyst development. IVC was continued at 38°C, 5% 
CO2, 5% O2. 
Materials & Methods 40 
 
2.12.10 Staging and selection of embryo recipients  
In this study thirteen female adult common marmosets were used as recipients for embryo 
transfer (ET). The recipient females used as surrogate mothers for the ET were chosen regard-
ing to their stage in their ovulation cycle. Ideal for ET are females at day 3-5 after ovulation. 
The approximal time of ovulation is determined by progesterone level measurement. Proges-
terone was measured from blood samples as described in 2.12.2. Recipient females were 
paired with vasectomized males or other females. 
2.12.11 Embryo Transfer (ET) and determination of pregnancy 
Starting on day 4 after IVF, the embryos were checked for the number of blastomeres to de-
termine proper and timely development, and for fluorescence, to determine proper GFP ex-
pression. Embryos were usually transferred to recipient females on day 5 after IVF (4 days 
after virus injection). For the embryo transfer (ET), properly developed embryos with a good 
fluorescence signal were used. ET was performed non-invasively through a transvaginal cath-
eter. 
After ET, the progesterone level of the recipient female was monitored (2.12.2) to check for 
embryo implantation. For the first measurement, on day 5-8 after ET, a progesterone level of 
about 20-50 ng/ml is expected. On day 7, day 14, day 21 after ET, Progesterone levels were 
also measured. A concentration of 40-80 ng/ml of progesterone indicates pregnancy. A pro-
gesterone level below 10 ng/ml at two consecutive weeks usually indicates the start of a new 
cycle, suggesting the loss of the embryo. Animals with a concentration between 10-40 ng/ml 
were further monitored and possible pregnancy was determined via ultrasound. Usually three 
weeks after ET the first ultrasound was performed to verify pregnancy. 
2.13 Lentivirus preparation 
2.13.1 Culture of 293T cells 
293T cells, a 293 human embryonic kidney (HEK) cell line that was transduced with simian 
virus 40 T-antigen, was used for lentivirus packaging. 293 T cells were cultured on Poly-L-
Lysine (Sigma-Aldrich) coated cell culture dishes in MEF medium. Cells were further pas-
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saged when a confluency of 70-90% was reached. For passaging, cells were first washed with 
5ml of 1 x PBS and then detached with 4ml Trypsin-EDTA (Gibco) for 5 min at 37 °C. 
MEF medium: 
 DMEM (Gibco) 
10% (v/v) FBS (Biowest) 
1% (v/v) Antibiotic-Antimycotic (Gibco) 
 
2.13.2 Lentivirus generation with 293T cells 
For generation of Lentivirus, 293T cells were transfected with the FuGENE 6 transfection kit 
(Promega) according to manufacturer’s instructions.  
For transfection, the cells were seeded on a ∅15cm dish with a density of 1x107 cells per 
∅15cm dish. For the transfection, 25µg pCAG-HIVgp plasmid DNA, 25µg pCMV-VSV-G-
RSV-Rev plasmid DNA and 50µg PL-SIN-EOS-C(3+)-EiP plasmid DNA were diluted to a 
total volume of 2.5 ml in OptiMEM (Life-Technologies). 300 µl FuGENE® 6 Transfection 
Reagent was added to 2.2 ml OptiMEM. Afterwards, the vector OptiMEM solution and the 
FuGENE® 6 OptiMEM solution were gently mixed and incubated for 20 min at RT. Subse-
quently the solution was added dropwise to two 15cm dishes of 293T cells (2.5ml per 15cm 
dish). Transfected cells were incubated in 30ml MEF medium over night at 37 °C, 5% CO2. 
On Day 1 post transfection the 30ml MEF medium were discarded and 30ml new medium 
were added. On Day 2 post transfection the 30ml medium were collected and new medium 
was added to the cells. On Day 3 post transfection the 30ml medium were collected and 
pooled with the medium from Day 2. The cells were discarded. The pooled supernatant, con-
taining viral particles, was filtered through a 0.22µm corning filter (Corning). Afterwards, the 
filtered medium was ultracentrifuged for 2h at 50000g and 4°C. After centrifugation the su-
pernatant was discarded and the virus pellet was resuspended in 60µl ISM1 (Origio). Aliquots 
of 12µl were stored at -80°C. 
2.13.3 Lentivirus titer calculation with the Lenti-X™ qRT-PCR Titration 
Kit 
To calculate the titer of the generated EOS-EiP lentivirus, the Lenti-X™ qRT-PCR Titration 
Kit (Clontech, USA) was used according to manufacturer’s instructions. 
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2.14 CRISPR/Cas9 associated procedures 
2.14.1 Identifying potential gRNA sequences 
For CRISPR-Cas9 gRNA the potential target sites have the sequence of 5’-
NNNNNNNNNNNNNNNN-NGG on the leading strand or. The common marmoset DNA 
sequences of interest were obtained from Ensemble (http://www.ensembl.org/). Possible target 
sites in these sequences were analyzed with the CRISPR design tool (http://crispr.mit.edu/), 
provided by the Zhang Lab. For a given sequence the CRISPR design tool provides a list of 
all potential target sites and grades these regarding to their potential off-target effects (poten-
tial of targeting other (unintended) sequences in the target genome). The CRISPR design tool 
does not contain the common marmoset genome, therefore the human genome was used as 
reference and potential target sites were subsequently compared to the marmoset genome. 
2.14.2 gRNA design and assembly 
Suitable target sequences, identified as mentioned in 2.14.1, have been ordered from Sigma-
Aldrich as top and bottom oligos (Figure 2.3). Therefore nucleotides necessary for later pro-
cessing were added to the 20bp long target sequences as described in Figure 2.3. The top and 
bottom guide oligos were annealed and phosphorylated. Therefore, 1 µl of the top and 1µl of 
the bottom gRNA oligo (100 µM), 1 µl of 10x T4 Polynucleotide Kinase Reaction Buffer 
(NEB), 0.5 µl T4 Polynucleotide Kinase, and 6.5 µl ddH2O were mixed. The reaction was 
incubated at 37 °C for 30 minutes, followed by 5 minutes at 95 °C and ramped down to 25 °C 
at a speed of 5 °C/minute. For the ligation of the annealed top and bottom oligos into the 
PX459 plasmid (2.14.3), the annealed oligos were diluted 1:200 in ddH2O. All used oligos are 
listed in 6.1. 
Materials & Methods 43 
 
 
Figure 2.3. Overview for cloning of the guide sequence oligos into the plasmid containing Cas9 and the sgRNA 
scaffold (pSpCas9(BB)). The guide oligos (sequence marked in blue) contain overhangs for the ligation into the 
pair of BbsI sites in pSpCas9(BB). Digestion of pSpCas9(BB) with BbsI (excised fragment outlined in blue) 
allows the insertion of the annealed guide oligos. To aid the selection of transfected cells versions of 
pSpCas9(BB) containing GFP or a puromycin resistance gene are available. Here the plasmid pSpCas9(BB)-2A-
Puro (PX459) was used. (From Ran et al. 2013) 
2.14.3 Cloning gRNA into pSpCas9(BB)-2A-Puro (PX459) plasmid 
The annealed gRNA was cloned into the PX459 plasmid as shown in Figure 2.3. The PX459 
plasmid was a gift from Feng Zhang (Addgene plasmid # 48139). 1 µg PX459 plasmid was 
digested with 10 U BbsI (NEB, #R0539S) in NEB Buffer 2 at 37°C for 30min. Next the en-
zyme was heat inactivated at 65°C for 20 min. Afterwards, the digested PX459 plasmid was 
dephosphorylated as described in 2.4.2. The digested and dephosphorylated plasmid was elut-
ed from a 1% agarose gel (2.7.1) as described in 2.7.2. Next, the annealed guide oligos 
(2.14.2) were ligated into the plasmid (Figure 2.3) as follows: 50ng PX459 (BbsI digested and 
dephosphorylated), 1µl diluted gRNA oligos (1:200), 1µl Ligase buffer and 1µl T4 Ligase 
(2.4.4) were mixed and filled up with ddH2O to a total 10µl. The reaction was incubated for 
1h at room temperature. Afterwards the plasmid was treated with Plasmid-Safe™ ATP-
Dependent DNase (Epicentre) as described in 2.4.3. Next the plasmid was transformed into 
E.coli cells (2.3.3), colonies were picked and a mini preparation was performed (2.5.1). The 
prepared plasmid DNA was send in for sequencing as described in 2.11. Sequence verified 
Materials & Methods 44 
 
plasmids were transformed into E.coli cells (2.3.3) and afterwards used for Maxi-preparation 
as described in 2.5.2. After Maxi-preparation plasmids were ready for transfection (2.15.6.1) 
into cells. 
2.14.4 ssODN design 
To achieve CRISPR/Cas9 based homology-directed repair (HDR), homologous templates 
have to be present in the cell. As homologous templates, single stranded DNA oligo nucleo-
tides (ssODNs) were designed using Serial Cloner 2.6 
(http://serialbasics.free.fr/Serial_Cloner.html). The ssODNs used in this study had a total 
length of 92 and 162 nucleotides, respectively, with two homology arms flanking the se-
quence containing the mutation of interest. The ssODNs were ordered from Sigma Aldrich. 
The used ssODNs are shown in Figure 3.7 and are listed in 6.1. 
2.14.5 T7 endonuclease I assay 
T7 endonuclease I was used to check CRISPR/Cas 9 treated cells for induced mutations. T7 
endonuclease I (T7EN1) recognizes mismatches resulting from hybridization of wt DNA and 
mutated DNA and digests the DNA at these mismatches (Figure 2.4). The DNA target of in-
terest was PCR amplified as described in 2.2.1. For the hybridization reaction, 2 µl NEBuffer 
2 (NEB), 200 ng of purified PCR product, and ddH2O were added to a total volume of 19,3µl. 
The hybridization reaction was incubated for 5 minutes at 95 °C, ramp down to 85 °C at 2 
°C/s and ramp down to 25 °C at 0.1 °C/s, followed by a hold at 4 °C. Following the hybridiza-
tion reaction, 0.7 µl (10U) T7 endonuclease I were added and the solution was incubated for 
15 minutes at 37 °C for digestion. Afterwards, the reaction was stopped by adding 1 µl 0.5 M 
EDTA. Subsequently, the sample was loaded onto a 1 % agarose gel for gelelectrophoresis 
(2.7.1) to investigate resulting DNA fragment lengths (Figure 2.4). The used primer pairs are 
listed in 6.1. 
 
Fig. 2.4. Simplification of T7EN1 digestion for CRISPR/Cas 9 activity control. Heterogenous population of 
DNA is denaturated and rehybridized. Rehybridized DNA fragments contain sequence mismatches. T7EN1 
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recognizes these mismatches and digests DNA at these positions. The resulting different fragment lengths are 
proof of CRISPR/Cas9 activity 
2.14.6 Single clone sequencing analysis 
To be able to sequence single clone DNA, PCR amplified DNA from gRNA+ssODN nu-
cleofections was ligated into pcDNA3.1(-). PCR primers containing restriction sites for NheI 
and XhoI were used to PCR amplify the region of interest. PCR products and pcDNA 3.1 
plasmid were both digested with NheI and XhoI as described in 2.4.1. Next the PCR products 
were ligated into pcDNA 3.1(-) as described in 2.4.4. The pcDNA3.1(-) plasmids containing 
the sequence of interest were transformed into NEB10-beta E.coli cells as described in 2.3.3. 
Single clones were picked and DNA was prepared (2.5.1). The clones were digested with ScaI 
(2.4.1) analysed on an agarose gel (2.7.1) to prescreen for CRISPR/Cas9 mediated HDR. Pu-
tative positive clones were sequenced as described in 2.11. The used primer pairs are listed in 
6.1. 
2.15 Cell culture 
The following cells were used in this study: 
Fibroblast cells: 
Primary fibroblasts from the common marmoset 
Primary fibroblasts from the putative transgenic common marmosets I780tgM, I779tgM and 
I664tgF 
Pluripotent cells: 
cjes001 common marmoset ES cell line (Gift from Erika Saski (Müller et al., 2009)) 
iPSC#3.5   iPS cell line from the common marmoset provided by Katharina Debowski (De-
bowski et al., 2015) 
Cells for lentivirus generation 
293T cells    first described by (DuBridge et al., 1987) 
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2.15.1 Culture conditions for primary fibroblasts (Callithrix jacchus) 
Primary fibroblasts were isolated from skin biopsies of the common marmoset. The skin was 
washed in 1 x PBS (Life-Technologies) and remaining hair was removed from the skin by use 
of razor blades. The skin was cut into pieces of 1 x 1 - 2 x 2 mm. Single pieces of skin were 
transferred to a tube, containing 950 μL DMEM. Collagenase IV (Gibco) was dissolved in 
1 x PBS to a final concentration of 5 mg/ml. Collagenase IV (50 μl) was added to the skin 
pieces. Skin was incubated (37 °C; 800 rpm) for at least 1 h. Cells were centrifuged at 300 x g 
for 5 min at room temperature.  The supernatant was discarded. Two cell pellets were seeded 
per culture dish (∅ 5 cm), in 3 ml M10. The cells were incubated at 37 °C, 5% CO2. M10 
medium was changed twice a week. At approximately 90% confluence, cells were detached 
and distributed to new dishes. Therefore cells were first washed with 3 ml of 1 x PBS and 
then detached with 1ml TrypLE Express (Gibco; 6 min; 37 °C). For long-term storage, cells 
were kept in freezing medium. Aliquots of 2 x 106 cells/ml were stored at -150 °C. 
 
Freezing medium:                                               
 DMEM, GlutaMAX™ 
25% FBS 
10% (v/v) DMSO 
  
 
M10 medium: PBS (pH 7.4): 
 DMEM, GlutaMAX™ 137 mM NaCl 
10% (v/v) FBS (Gibco) 2.7 mM KCl 
2 mM L-Glutamine (Gibco) 10 mM Na2HPO4 
1% Penicillin/Streptomycin (Gibco) 1.8 mM KH2PO4 
1% non-essential amino acids (Gibco)   
2.15.2 Mouse embryonic fibroblasts (MEFs) 
To generate MEFs, embryos from CD1 mice at stage E12.5 were used. The embryos were 
washed in 1xPBS and the head as well as the hematopoietic organs of each embryo were re-
moved. The rest of the embryos were minced and transferred into fresh 1x PBS. Next, the 
minced embryos were centrifuged for 20 min at 400 x g at room temperature. The supernatant 
was discarded and the pellet was resuspended in 0.05 % Trypsin/EDTA and incubated for 20 
min at 37 °C. To stop the Trypsin/EDTA reaction M10, 5% (v/v) FBS and DNaseI (Roche, 
100Kunitz units/ml), were added. Cells were Incubated for 10 min at 37°C and afterwards 
pelleted at 300 x g at room temperature. Afterwards, the cells were seeded in fresh M10 me-
dium. For γ irradiation, the cells needed to be in passage 0-4 and were irradiated with 30 Gy 
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(5Gy/min). After irradiation cells were centrifuged at 300 x g (room temperature) for 15 min. 
For cryo-preservation, cells were resuspended in 90% FBS/10% DMSO and frozen at -150°C 
and a density of 6 x 106 cells/ml. 
For usage as feeder cell layer, the MEFs were thawed and seeded on gelatin (0,5 % w/v; 
Fluka, #48720-100G-F) coated cell culture dishes. The cells were seeded at a density of 
50.000 to 100.000 cells per cm2 in M10, usually 1-3 days prior to use. 
M10: 
 DMEM, GlutaMAX™ 
10% (v/v) FBS (Gibco/BRL) 
2 mM L-Glutamine (Gibco/BRL) 
1% Penicillin/Streptomycin (Gibco/BRL) 
1% non-essential amino acids (Gibco/BRL) 
 
2.15.3 Culture conditions of pluripotent cells 
Pluripotent cells were cultured on MEFs in ESM medium. Cells were incubated at 37 °C, 8 % 
CO2, 5 % O2. Medium was changed every second day. When close to confluency, cells were 
washed with 1x PBS and incubated with Stem Pro Accutase (Gibco) for 4 min at 37 °C, to 
detach the cells. Cells were pelleted for 5 min at 200 x g, the supernatant was discarded and 
cells were resuspended in ESM medium. The desired amount of cells was plated on new feed-
er cells.  
Aliquots of frozen pluripotent cells were rapidly thawed at 37 °C and incubated in ESM me-
dium. For cryopreservation, cells were harvested at 60-70 % confluency. Cells were detached 
as described above. The cell suspension was then pelleted for 10 min at 200 x g, resuspended 
in freezing medium (2.15.2) and frozen. Cells were stored at -150°C 
ESM: 
 KNOCKOUT-DMEM (Gibco)  
20% Knockout Serum Replacement (Gibco) 
1 mM MEM-NEAA (Gibco)  
2mM GlutaMAXTM-I (Gibco)  
50µM 2-Mercaptoethanol (Gibco)  
1%(v/v) 
0.25µg/ml 
Pen Strep (Gibco)  
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2.15.4 Derivation of clonal cell lines  
Cells were detached from culture dishes as described in 2.15.1. Afterwards single cells were 
transferred to 24 well multi well plate (MWP) to obtain monoclonal cell lines, using a fine 
glass pipette connected to a plastic tube. 
2.15.5 Population-doubling level (PDL) calculation 
Fibroblasts were passaged in Petri dishes (∅10cm) as described in 2.15.1. For each passage 
2,5x105 cells /dish were seeded. When reaching confluency, cells were harvested and counted 
before they were seeded again at 2,5x105 cells /dish for the next passage. Outgoing from con-
secutive counts the PDL was calculated as follows: PDL(n/n-1) = log (Nf/N0)/log 2, where 
n=passage number, Nf=final number of cells, N0 = number of cells seeded at passage (Bis-
choff et al., 2012).  
2.15.6 Cell transfection 
2.15.6.1 Transfection with AmaxaTM 4D NucleofectorTM (Lonza) 
Common marmoset primary fibroblasts were transfected with the AmaxaTM 4D Nu-
cleofectorTM (Lonza) with the P2 Kit for primary mammalian fibroblasts (Lonza). Cells were 
detached using TrypLE Express (2.15.1) (Gibco) and counted. For each nucleofection 1 x 106 
cells were centrifuged for 10 min, at 90g at room temperature. The pelleted cells were resus-
pended in 100μL nucleofection solution (buffer 2), plasmid DNA was added and the solution 
was transferred to a nucleofection cuvette. For nucleofection the programme CA-137 was 
used. Afterwards, cells were incubated at room temperature for 10 minutes and were resus-
pended in 500 μL prewarmed M10. Cells were plated on dishes or multi well plates (MWP). 
2.16 Reprogramming of fibroblasts to induced pluripotent stem 
(iPS) cells 
Fibroblasts were nucleofected with one of the piggyBac reprogramming constructs and the 
transposase, PBase, catalyzing the integration of the reprogramming factors (2.4) (Figure 3.2). 
The AmaxaTM 4D NucleofectorTM (Lonza) (2.15.6.1) was used for the transfections. After nu-
cleofection, cells were cultured in M10 medium and selected with 1-2µg/ml puromycin for 
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five days on cell culture dishes. Cells were transferred onto MEF coated culture dishes (2-6 × 
104 cells per Ø10cm culture dish) and cultured in ESM (2.15.3) at 37°C, 8% CO2, 5% O2. For 
the first six days of culture, ESM was supplemented with 2mM valproic acid (Calbiochem). 
Developing colonies were picked manually from day 28 on. Picked colonies were transferred 
to fresh MEF feeder layers for further culture. Cells were further passaged with StemPro Ac-
cutase as described in 2.15.3. 
2.17 Immunofluorescence staining of cultivated cells 
Fibroblasts were detached with TrypLE (2.15.1) and seeded on a 48well MWP. Pluripotent 
cells were detached with StemPro Accutase (2.15.3). After the cells reach an appropriate den-
sity the medium was removed and cells were washed twice with PBS. Cells were fixed in 2-
4% PFA (in PBS) for 10-30 min. After PFA fixation the cells were washed twice with PBS. 
Afterwards, cells were treated with 0.1% TritonX-100 for 10-15 min at RT followed by wash-
ing twice with PBS. Primary antibodies were diluted in PBS + 5% BSA pipetted onto the cells 
and incubated over night at 4°C. Afterwards the cells were washed twice with PBS. The sec-
ondary antibody, diluted in PBS + 5% BSA, was added to the cells and incubated for 20 min 
at room temperature in the dark. The cells were washed twice with PBS and subsequently 
stained with 5% DAPI in PBS for 1-2 min at room temperature. Afterwards, cells were 
washed twice with PBS and mounted with Citifluor mountant medium (CITIFLUOR). Mi-
croscopy images were taken with a Zeiss Observer Z1 (Zeiss). The used primary antibodies 
and their dilutions were: TERT (abcam, #ab32020, 1:200), OCT4 (Cell Signalling, #2890, 
1:100), NANOG (Cell Signaling, #4903, 1:300), LIN28 (Cell Signaling, #3978S, 1:70), TRA-
1-60 (eBioscience, #14-8863, 1:50), SSEA-4 (Merck Millipore, #MAB4304, 1:50). The used 
secondary antibodies were:  AlexaFluor488 goat anti-mouse (Life Technologies, #A10680), 
AlexaFluor488 donkey anti-rabbit (Life Technologies, #A21206), AlexaFluor488 donkey 
anti-mouse (Life Technologies, #A21202), AlexaFluor594 donkey anti-rabbit (Life Technol-
ogies, #A21207). All secondary antibodies were diluted 1:200. 
2.18 Flow cytometry of iPS cells 
For flow cytometry, iPS cells were first detached with Stem Pro Accutase as described in 
2.15.3. The cells were incubated in ESM for 2h on gelatin-coated petri dishes. After this step 
the majority of remaining MEFs were attached to the petri dish and the iPS cells were still in 
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suspension. Induced PS cells in suspension were pelleted at 200 x g for 5 min. Cell pellets 
were resuspended in Stem Pro Accutase and incubated for 30 min at 37°C (under constant 
rotation). Cells were centrifuged at 200 x g for 5 min and resuspended in PBS. To obtain 
mainly single cells, the cells were pipetted through a 40 µm cell strainer. Cells were centri-
fuged at 200 x g for 5 min and fixated in 0.37% PFA (in PBS). The flow cytrometric meas-
urement was performed with a LSRII cytometer (BD Biosciences). Flow cytometry data anal-




3. Results  
3.1 Transgenesis in the common marmoset  
The experiments for the generation of transgenic common marmosets were performed in the 
labratory of Prof. Erika Sasaki at the Central Institute for Experimental Animals (CIEA) in 
Kawasaki, Japan. The goal of my work at the CIEA was to generate transgenic common 
marmosets carrying the EOS-EiP transgene. For the successful generation of a transgenic 
marmoset it was crucial to learn and perform the different required methods in perfection. The 
used methods are listed in 2.12. 
3.1.1 EOS-EiP virus injection and embryo check 
For the generation of transgenic common marmosets, overall 16 superovulated animals 
(2.12.3) were used as oocyte donors for oocyte collection (2.12.5). Collected oocytes were in 
vitro matured (2.12.6) and used for in vitro fertilization (IVF) (2.12.7). IVF embryos showing 
proper development, i.e. the formation of the maternal and paternal pronuclei (2.12.8), were 
used for virus injection. To integrate the EOS-EiP (Figure 1.2) transgene into the marmoset 
embryo genome, EOS-EiP self-inactivating lentivirus was generated as described in 2.13.2. 
The titer of the used virus was 2.8x109 infectious units/ml (IFU/ml) (2.13.3). In order to pre-
pare the embryos for virus injection they were transferred to drops of 0.25 M sucrose in PB1 
medium. The hyperosmotic sucrose solution enlarges the perivitelline space and allows easier 
virus injection (Figure 2.2 C) (2.12.9). Overall, 72 one-cell stage embryos were injected with 
the EOS-EiP virus (Table 1). After injection, embryos were incubated in ISM1 medium for in 
vitro culture (IVC) (2.12.9). The IVC embryos were checked for proper development and 
eGFP signal (indicating successful EOS-EiP integration) starting 72 hours after injection. 
3.1.2  Embryo transfer (ET) resulted in three newborn common 
marmosets 
Seventy-two embryos were injected with the lentivirus. Twenty-five (34.7%) of them showed 
timely development combined with a clear eGFP signal (Table 1). These embryos were used 
for embryo transfer (ET) (2.12.11). Figure 3.1 A+D show examples of embryos used for ET. 
Overall, 25 EOS-EiP virus injected embryos were transferred into overall 13 surrogate moth-
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ers (Table 1). Five to eight days after ET the first blood samples from surrogate mothers were 
taken for progesterone measurement in order to determine pregnancy status. Starting around 
three weeks after ET, the putative pregnant females were also monitored using ultrasound. 
Figure 3.1 C+G show the ultrasonographic pictures of the implantation site and the embryo. 
The Transfer of the 25 embryos resulted in three pregnancies from four transferred embryos 
(16% of the overall 25 transferred embryos): two singletons and one twin pregnancy. One of 
the singleton pregnancies resulted in an abortion 71 days after ET (Table1).  
 
Figure 3.1. Transgenic common marmosets. A) Brightfield and Fluorescence pictures of EOS-EiP virus in-
jected embryos. The green circle marks an uninjected wildtype control embryo, red circles the eGFP-positive 
embryos used for retransfer. One resulted in the birth of newborn I664tgF. Bar= ca. 100µm B) Newborn I664tgF 
(♀). C) Ultrasound picture of surrogate mother the I3388F, 48 days post retransfer of the embryos shown in A). 
White arrow indicates implanted embryo. D) Brightfield and Fluorescence pictures of EOS-EiP virus injected 
embryos. The green circle marks an uninjected wildtype control embryo, red circles the embryos used for re-
transfer and resulting in the birth of newborns I779tgM and I780tgM. Bar= ca. 100µm E) Newborn I780tgM 
(♂). F) Newborn I779tgM (♂). G) Ultrasound picture of the surrogate mother I3488epF, 50 days post retransfer 
of embryos shown in D). White arrow indicates implanted embryo. 
Two of the surrogate mothers successfully delivered offspring with a total number of three 
newborns (12% of the total 25 transferred embryos) (Table 1). The first putative EOS-EiP 
transgenic common marmoset (I664tgF) was born on November 12th 2013, two more 
(I779tgM, I780tgM) were born on November 24th 2013. Figure 3.1 B+E+F show the neonatal 
common marmosets. Animal I780tgM was euthanized eight days after birth due to a develop-
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ing sepsis. Due to time constrains, the genotyping of the transgenic animals was not per-
formed at the CIEA but later at the German Primate Center in Goettingen using fibroblasts of 
the animals. 
Table 1. Overview of number of used animals, virus injected embryos, retransferred embryos, 
pregnancies from retransfers and newborns from retransfers 
 
3.2 Generating iPS cells from EOS-EiP transgenic common 
marmoset fibroblasts 
After we generated putatively transgenic common marmosets carrying the EOS-EiP 
transgene, we wanted to reprogram fibroblasts of these animals. The reprogramming experi-
ments were performed at the Stem Cell Biology Unit of the German Primate Center in 
Goettingen.  
3.2.1 Analysis of fibroblasts from EOS-EiP positive marmosets  
Skin biopsies of the juvenile animals I664tgF and I779tgM were taken to obtain fibroblast 
cells for reprogramming experiments. From the animal I780tgM, skin samples were taken 
after euthanization. The skin biopsies and subsequent fibroblast cell culture was performed by 
employees of the CIEA. The fibroblast cells of the animals I664tgF and I779tgM, together 
with the fibroblast cells of the euthanized animal I780tgM were provided by the CIEA for 
further use at the German Primate Center. The cells of the putatively EOS-EiP transgenic 
marmosets were further analyzed and used to generate induced pluripotent stem (iPS) cells 
from these animals.  
Genomic DNA (gDNA) of the three different fibroblast cultures was prepared (2.6). The 
gDNA was used for genotyping by PCR (2.2) using primers specific for the EOS-EiP cassette. 
As shown in Figure 3.2 E, the genotyping PCR revealed the presence of an EOS-EiP specific 
DNA sequence in the samples of the animals I779tgM and I780tgM. The animal I664tgF was 
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negative for EOS-EiP. The fibroblasts of animal I664tgF were not further included in this 
study. 
3.2.2 Reprogramming of EOS-EiP positive fibroblasts using the 
piggyBac transposon system 
EOS-EiP should drive eGFP expression in toti- and pluripotent cells, i.e. cells of the early 
embryo and pluripotent stem cells. To show the EOS-EiP activity in pluripotent stem cells 
(Hotta et al., 2009), I reprogrammed the EOS-EiP transgenic fibroblast using the piggyBac 
transposon system. For this work two different piggyBac (1.2.2) constructs were used: One  
 
Figure 3.2. A)-B) Constructs used for reprogramming. Reprogramming factors are under control of the CAG 
promoter (Pcag). pA: poly A signal; 5ˈ-TR: 5ˈ-terminal repeat; 3ˈ-TR: 3ˈ-terminal repeat; S: SOX2; O: OCT4; 
K: KLF4; M: c-MYC; L: LIN28; N: NANOG; P: puromycin resistance gene. The stop codons of the first three 
(A) or five (B) reprogramming factors are substituted with coding sequences for 2A peptides (F2A, T2A, E2A) 
C) Expression of the Transposase (PBase) is driven by the Cytomegalovirus promoter (Pcmv); IRES: internal 
ribosomal entry site; tdTomato: red fluorescence protein used for transfection control. D) Morphology compari-
son of iPS cells and ES cells. The generated iPS cell line 780.SOKM.6 and the ES cell line cjes001 show similar 
morphology. E) Genotyping PCR results. gDNA of fibroblasts of the three putative EOS-EiP transgenic animals 
was used for PCR with EOS-EiP specific primers, β-Actin was amplified as a loading control. Bars = 100µm (A, 




construct consisting of the four classical reprogramming factors SOX2, OCT4, KLF4 and c-
MYC (SOKM) (four factor construct) and one with the classical factors plus the two addition-
al factors LIN28 and NANOG (SOKMLN) (six factor construct) (3.2 A-B) previously shown 
to be necessary for reprogramming of common marmoset monkey cells (Tomioka et al., 2010) 
(1.3.2). Both constructs were generated by Katharina Debowski, the six factor construct was 
published in Debowski et al. 2015. Fibroblasts of the two EOS-EiP positive animals 
(I779tgM, I780tgM) were used for reprogramming with the two piggyBac constructs. Fibro-
blasts of both animals were nucleofected with either the six factor construct or the four factor 
construct and the transposase, called PBase, catalyzing the genomic integration of the repro-
graming cassette (2.16) (Figure 3.2 C). 
After transfection the I779tgM and I780tgM fibroblasts were treated and cultured as described 
in 2.16. For the cells transfected with the six factor construct the first cell colonies showing 
morphology similar to ES cells, were picked after 28 days of culture on MEFs. Overall 51 
colonies from six factor transfected cells were picked. The first colonies resulting from cells 
transfected with the four factor construct were picked after 91 days of culture on MEFs. 
Overall six colonies from four factor transfected cells were picked. From the picked colonies 
the two putative iPS cell lines 780.SOKM.5 and 780.SOKM.6 were generated. Both cell lines 
resulted from cells transfected with the four factor construct. Both showed a morphology 
comparable to ES cells and were passaged more then 30 times. A typical colony of the iPS 
cell line 780.SOKM.6 is shown in Figure 3.2 D. Further reprogramming experiments with the 
EOS-EiP positive fibroblasts resulted in multiple putative iPS cell lines generated with the six 
factor construct (data not shown). Generation of common marmoset iPS cells with the classi-
cal four factors was reported previously (Wiedemann et al., 2012; Wu et al., 2010). The fol-





Figure 3.3. Immunofluorescence staining of the iPS cell line 780.SOKM.6 and the ES cell line cjes001 (positive 
control). As negative control, wildtype fibroblasts were stained (pictures not shown). The staining shows similar 
expression of the key pluripotency factors OCT4, NANOG, and LIN28 and of the pluripotency markers TRA-1-
60 and SSEA-4 in the iPS cell line 780.SOKM.6 and the ES cell line cjes001. This indicates pluripotency of the 
780.SOKM.6 iPSCs. 
3.2.3 Common marmoset iPS cell analysis indicates pluripotency 
To show expression of reprogramming factors and surface pluripotency markers, immunoflu-
orescence (IF) staining of the iPS cells and the ES cell line cjes001 as positive control were 
performed. IF staining showed expression of the used reprograming factors OCT4, NANOG 
and LIN28 (Figure 3.3). The cells were also positive for the surface pluripotency markers 
stage specific embryonic antigen 4 (SSEA-4) and tumor rejection antigen-1-60 (TRA-1-60) 
(Figure 3.3). The stainings of the iPS cells and the ES cells (positive control) showed compa-
rable staining patterns and intensities (Figure 3.3). This marker expression pattern indicates 
reprogramming of the fibroblasts to pluripotency (compare with Debowski et al., 2015). As 
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negative controls for IF staining common marmoset wildtype fibroblasts were used. In the 
negative controls no expression was detectable. 
The cells nucleofected with the reprogramming vectors contain two versions of the factors 
present in the reprogramming cassette: an endogenous gene and the exogenous cDNA provid-
ed by the introduced vector. To check for the origin of the expressed pluripotency factors in 
the iPS cells, we performed several RT-PCRs (2.9, 2.2) either with primers specific for the 
reprogramming factors present in the reprogramming cassette or with primers specific for the 




Figure 3.4. Characterization of pluripotency factor expression by RT-PCR. cDNA from the iPS cell lines 
(780.SOKM.5, 780.SOKM.6), the ES cell line cjes001, common marmoset fibroblasts and MEFs was used as 
template DNA. Primer pairs specific for the endogenous factors (SOX2, OCT4, KLF4, C-MYC, LIN28, NANOG) 
or the reprogramming cassette (S-O, L-N) were used. As a loading control, β-Actin was amplified. For all sam-
ples –RT controls were used. SOX2, KLF4 c-MYC were also detected in cDNA from common marmoset fibro-
blasts. Only transcripts derived from the four factor reprogramming cassette were detected in the iPSCs, but no 
transcripts specific for the six factor reprogramming cassette. This further proves successful four factor repro-
gramming. 
 
factors annealed to untranslated regions of the mRNA, which are not present in the repro-
gramming cassette. As controls we used the ES cell line cjes001 and common marmoset fi-
broblasts. As shown in Figure 3.4, all generated iPS cell lines express the reprogramming fac-
tors SOX2, OCT4, KLF4, c-MYC, LIN28 and NANOG endogenously. The RT-PCR specific 
for the exogenous reprogramming factors present in the piggyBac cassette showed that in the 
780.SOKM.5 and 780.SOKM.6 line only SOX2-OCT4 (S-O) were expressed, LIN28-NANOG 
(L-N) was not detected (Figure 3.4). These results further indicate that the cells were repro-
grammed by only the four factor construct. 
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3.2.4 EOS-EiP transgenic iPS cell lines lack detectable GFP fluorescence 
The EOS-EiP transgene is supposed to be active in pluripotent cells. Its activity is reported by 
enhanced Green Fluorescence Protein (eGFP) expression. Primary iPS cell colonies on MEFs 
(before picking) as well as the two putative four factor iPS cell lines were frequently checked 
for eGFP activity. Unfortunately no eGFP signal was detectable. By fluorescence microscopy 
of the iPS cell lines only green and red auto fluorescence was detectable. Similar autofluores-
cence was detectable in other common marmoset iPS cells lacking GFP (Figure 3.5 A). In 
order to find out on which level the eGFP reporter system failed, the iPS cells were checked 
for eGFP mRNA expression by RT-PCR (2.9, 2.2). The RT-PCR results indicate eGFP ex-
pression in both iPS cell lines (Figure 3.5 B). Because no fluorescence was detectable by fluo-
rescence microscopy, we performed flow cytometry analysis (2.18) to determine if a small 
fraction of cells exhibit eGFP fluorescence. Moreover, flow cytometry is more sensitive than 
visual fluorescence microscopy. However, the flow cytometry analysis showed no significant 
eGFP signal (Figure 3.5 C) above the background fluorescence present in the negative control 
ES cell line cjes001. Finally, the mRNA expression level of eGFP was analyzed by real-time 
quantitative PCR (2.10) to determine the relative eGFP expression level in the iPS cells. GFP-
expressing fibroblasts were included as positive control, and the ES cell line cjes001 as nega-
tive control. Compared to the negative control, GFP expression was slightly increased in the 
iPS cell lines. However, GFP expression in the iPS cells was only approximately 1/100 of the 
GFP expression in the positive control (Figure 3.5 D). These results indicate an expression 
level of GFP in the iPS cell lines below the detection limit of the microscopic fluorescence 
detection system, equipped with a highly sensitive camera, as well as below the detection lim-





Figure 3.5. A) Autofluorescence in the iPS cell line 780.SOKM.6 and the iPS cell line iPSC#3.5. An overlay of 
detected green and red fluorescence is shown as well as the respective phase contrast images. B) GFP RT-PCR. 
cDNA from the iPS cell lines (780.SOKM.5, 780.SOKM.6), the ES cell line cjes001, common marmoset fibro-
blasts and MEFs was used as template DNA. For amplification primer pairs for eGFP were used. As a loading 
control β-Actin was amplified. For all samples –RT controls were used. In both iPS cell lines eGFP was detect-
ed) Flow cytometry analysis of the generated iPS cell lines. Shown is the site scatter (SSC) on the y-axis against 
GFP intensity on the x-axis. D) Real-time quantitative PCR for GFP. GFP expression levels in the iPS cell lines 
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were compared to levels in GFP positive fibroblasts and the GFP negative ES cell line cjes001. The standard 
error of measurement is shown for the iPS cells and ES cells.  
To determine if sequence re-arrangements in the integrated EOS-EiP cassette may cause the 
low levels of eGFP expression, relevant parts of the expression construct integrated into the 
iPS cells´ genome were sequenced. The EOS promoter region (early transposon promoter + 
OCT4 and SOX2 enhancer regions) and the eGFP open reading frame were PCR amplified 
(2.2), using gDNA samples of the iPS cell lines, and subsequently sequenced (2.11). The re-
sults showed the expected sequence, i.e. no sequence rearrangements were detectable (Data 
not shown).  
In summary of this part, it was shown that EOS-EiP transgene is present in the iPS cell lines. 
However, eGFP mRNA expression is severely reduced in the iPS cell lines compared to fi-
broblasts with detectable GFP activity. The reduced eGFP mRNA expression leads to unde-
tectable eGFP activity. The reason for the low eGFP mRNA expression in the iPS cell lines is 
currently not known.  
 
3.3 Targeted gene modification in common marmoset fibroblasts  
Another new and very promising method for targeted gene modification is the CRISPR/Cas 9 
system. It allows gene modification in basically all organisms, and was applied in this study 
to the common marmoset monkey. The target of interest in this study was the gene Leucine-
rich repeat kinase 2 (LRRK2), a gene associated with Parkinson’s disease (PD). Mutations in 
LRRK2 are the most common genetic cause for PD, with the point mutation Gly2019Ser be-
ing the most prevalent among them (Healy et al., 2008; Kett and Dauer, 2012) (1.4.2). 
3.3.1 CRISPR/Cas9 LRRK2 gRNA efficiently generates gene mutation 
in common marmoset fibroblasts 
For the use of the CRISPR/Cas9 system first the guideRNAs (gRNA) guiding the Cas9 nucle-
ase to the target of interest were generated (2.14.1, 2.14.2). We designed two gRNAs, one at 
position 86 (po86) of the LRRK2 exon 41 and one at position 113 (po113) of exon 41 (Figure 
3.6 A). The position of the gRNAs was defined as the starting point (nucleotide number) of 
the gRNAs in the exon 41. As described in detail in chapter 2.14.3, the gRNAs were subse-
quently cloned into the pSpCas9(BB)-2A-Puro (PX459) plasmid (gift from Feng Zhang 
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(Addgene plasmid # 48139)). The PX459 Plasmid contains the Cas9 nuclease as well as the 
gRNA scaffold and, after cloning, the gRNA (Figure 2.3). Therefore a single plasmid is suffi-
cient for CRISPR/Cas9 mediated gene targeting. 
The two plasmids (PX459_po86, PX459_po113) containing the different gRNAs (LRRK2 
gRNA po86, LRRK2 gRNA po113) were sequenced to verify successful and correct cloning 
(data not shown). To test the CRISPR/Cas9 system common marmoset fibroblasts were trans-
fected with one of the two CRISPR/Cas9 plasmids (2.15.6.1). Preliminary experiments 
showed that the puromycin resistance in the PX459 plasmid was not sufficient to efficiently 
select for positively transfected cells. No transfected cells survived puromycin selection. To 
achieve efficient selection I started cotransfecting fibroblasts with a CRISPR/Cas9 plasmid 
and a plasmid containing a strong puromycin resistance. In a cotransfection usually both 
plasmids  
 
Figure 3.6. A) Schematic overview of the gRNAs targeting LRRK2 exon 41. PAM sequences are underlined 
and highlighted in blue. gRNA target sequences are highlighted in red. B) T7EN1 assay. Detection of 
CRISPR/Cas9 mediated gene modification by T7EN1 cleavage assay. As template gDNA of fibroblasts trans-
fected with LRRK2 gRNA po113, LRRK2 gRNA po86 and untransfected wildtype fibroblasts (negative control) 




or none are inserted into the cells, allowing to efficiently select for transfected cells even if 
only one plasmid contains the resistance gene.  
The transfected cells were selected with puromycin for 3-4 days post transfection. Afterwards 
the cells were grown to confluency and harvested for genomic DNA extraction (2.6). The 
genomic DNA was used for PCR amplification (2.2) of the LRRK2 exon 41 region containing 
the gRNA target sites. The amplified DNA was analyzed using the T7 endo-nuclease 1 
(T7EN1) cleavage assay to test for site-specific gene modifications (2.14.5). The cleaved 
DNA bands shown in Figure 3.6 B indicate the expected activity of CRISPR/Cas9 through 
non-homologues end joining (NHEJ) (1.2.3). This demonstrates the functionality of the 
CRISPR/Cas9 system in common marmoset monkey fibroblasts. 
3.3.2 CRISPR/Cas9 based integration of ssODN HDR donors into the 
LRRK2 gene was unsuccessful in common marmoset fibroblasts 
The activity and general functionality of the CRISPR/Cas9 system was shown in chapter 
3.3.1. As described in the introduction (1.2.3), the CRISPR/Cas9 system can also be used to 
introduce point mutations or whole genes into a target genome by homology-directed repair 
(HDR). We designed single stranded oligodeoxynucleotides (ssODNs) as homologous for the 
introduction of the LRRK2 Gly2019Ser point mutation (2.14.4). The ssODNs consisted of a 
12bp long sequence containing the LRRK2 point mutation as well as a point mutation knock-
ing out a ScaI restriction site, flanked by sequences homologues to the target sequence (Figure 
3.7 A+B). The homology arms were 75 NT (162 NT ssODN) and 40 NT (92 NT ssODN) 
long, respectively. The knockout of the ScaI restriction site was introduced to perform a pre-
screening of DNA clones by ScaI digestion, thereby reducing number of clones necessary for 
sequencing. To introduce the point mutations, the CRISPR/Cas9 LRRK2 gRNA plasmids 
were co transfected with the ssODNs and a puromycin resistance plasmid into common mar-
moset fibroblasts. The four combinations of LRRK2 gRNAs and ssODNS were: LRRK2 
gRNA po86 + ssODN 162NT, LRRK2 gRNA po86 + ssODN92, LRRK2 gRNA po113 + 
ssODN 162NT, LRRK2 gRNA po113 + ssODN 92NT. After selection with Puromycin for 
three to four days, the cells were grown to confluency and genomic DNA was extracted (2.6). 
To obtain single DNA clones, the sequence potentially containing the LRRK2 point mutation 
was cloned into the pcDNA 3.1(-) plasmid as described in 2.14.6. The obtained clones (every 
one only containing one LRRK2 DNA sequence) were digested with ScaI for prescreening 
(2.14.6). Different fragment lengths were found (data not shown). Uncut clones were regarded 
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being putatively positive for CRISPR/Cas9 HDR because the ScaI restriction site was inac-
tive, suggesting CRISPR/Cas9 mediated HDR. The putatively positive clones were sequenced  
 
Figure 3.7. A) Used single stranded oligodeoxynucleotides (ssODNs). ssODNs consist of a 12 bp long stretch 
containing the mismatches against the genomic DNA for LRRK2 Gly2019Ser mutation introduction and ScaI 
restriction site knockout. The flanking homologous arms were 75 NT (162 NT ssODN) and 40 NT (92 NT 
ssODN) long. B) Sequences of common marmoset fibroblasts from LRRK2 Gly2019Ser mutation knock-in 
experiments. Clones of the PCR products were prescreened by ScaI digestion and putatively positive clones were 
analyzed by DNA sequencing. Additionally, some control (Ctrl) clones (putatively negative for HDR) were 
sequenced for comparison reasons. The PAM sequences are underlined and highlighted in blue, the gRNA tar-
geting sequences in red, the position oft he ScaI restriction site is marked with a blue bar, the position of the 
Gly2019Ser mutation is marked with a yellow bar. The mutations carried by the ssODNs are highlighted in 





and aligned against the LRRK2 wt sequence to check for the introduction of the LRRK2 
pointmutation. Figure 3.7 B shows the alignment of sequences of putatively positive clones 
and several control clone (putatively negative) sequences. The sequencing results show that 
no sequence changes resulting from HDR were detectable. However, different deletions and 
insertions were detected indicating activity of CRISPR/Cas9 through NHEJ as described in 
3.3.1. Some putatively positive clones were false positive in the prescreening assay due to 
misligations or empty, religated plasmids. Overall 576 colonies were analyzed, 144 clones for 
LRRK2 gRNA po86 + ssODN 162NT, 216 clones LRRK2 gRNA po86 + ssODN 92NT, 96 
clones of LRRK2 gRNA po113 + ssODN 162NT, 120 clones LRRK2 gRNA po113 + ssODN 
92NT. 
3.4 Immortalization of common marmoset fibroblasts using 
piggyBac-mediated hTERT transgenesis  
As part of this study I wanted to immortalize common marmoset fibroblast by robust long-
term expression of human telomerase reverse transcriptase (hTERT) using the piggyBac trans-
poson system. Human TERT immortalization circumvents cell senescence and crisis and al-
lows virtually infinite cell proliferation. Such cells would allow long-term studies with fibro-
blast-like cells without the potential severe effects of cell senescence likely to occur in prima-
ry fibroblasts.  
3.4.1 Exogenous hTERT prolongs cell proliferation potential in common 
marmoset fibroblasts 
To immortalize common marmoset fibroblasts I used human telomerase reverse transcriptase 
(hTERT). For the hTERT transgene insertion into the fibroblast genome we used the piggyBac 
transposon system. The hTERT cDNA was cloned into the piggyBac transposon system as 
described in 2.4.5. 
Fibroblasts were cotransfected (2.15.6.1) with the piggyBac plasmid containing the hTERT 
cDNA (3.8 A) and the PBase plasmid (Figure 3.2 C) catalyzing the integration of the piggy-
Bac transposon system. After transfection, the transfected cells were puromycin selected for 
ten passages. The first generated cells were polyclonal (derived from different cells) and were 
named polyclonal hTERT cells. Additionally the polyclonal cells were clonally expanded as 
described in 2.15.4, to obtain monoclonal (derived from one cell) cell lines. Two monoclonal 
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cell lines (#1, #4) were generated and further passaged as well as the polyclonal cell line. The 
cell lines were passaged in parallel to non-transfected primary fibroblasts (as control). To ex-
amine whether the hTERT transfected cells have an extended ability to replicate, we calculat-
ed the population-doubling level (PDL) (2.15.5) to get an estimate of their proliferation poten-
tial. The PDL is an approximation of the occurring population doublings over time (passages). 
The same was performed for the control cells. As expected, the hTERT transfected cells clear-
ly show higher proliferation potential then primary fibroblasts (Figure 3.8 B). The hTERT 
transfected cells underwent several hundred population doublings until the experiments were 





Figure 3.8. A) piggyBac construct used for immortalization. Human TERT is under control of the CAG promoter 
(Pcag). pA: poly A signal; 5ˈ-TR: 5ˈ-terminal repeat; 3ˈ-TR: 3ˈ-terminal repeat;; P: puromycin resistance gene. 
B) hTERT Cell Population-doubling level (PDL). PDL was determined by using cell counts and the respective 
number of passages. PDL was calculated with the formula: PDL(n/n-1) = log (Nf/N0)/log 2; n=passage number, 
Nf=final number of cells, N0 = number of cells seeded at passage.  
 
lower number of population doublings, reaching only a PDL of 46 and 18, respectively (Fig-
ure 3.8). These experiments were performed over a timeframe of more than nine months. 
Phase contrast microscopy of the cells revealed a morphological change of the immortalized 
cells in comparison to proliferating fibroblasts. The immortalized cell lines exhibit a thin and 
“needle like” shape (Figure 3.9 A). Such changes in morphology could indicate changes in 
gene expression, as common in cancer cells. Images of non-proliferating fibroblasts in a high 
passage show the typical morphology of cells in senescence (Blagosklonny, 2006). They 
show an enlargement of the cytoplasm (cell hypertrophy), with change from the fibroblast 
typical narrow, drawn-out morphology to a broader, rounder morphology (Figure 3.9 A). The 
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immortalized cell lines still exhibit proliferation activity, even in high passages (Figure 3.9 
A). To determine hTERT transgenesis, I performed immunofluorescence (IF) staining using a 
TERT specific antibody (2.17). Staining was performed using the hTERT immortalized cell 
lines as well as fibroblasts and ES cells as controls (2.17). 
All three immortalized cell lines (polyclonal, #1, #4) showed expression of TERT (Figure 3.9 
B). Additionally, it was observed that the hTERT immortalized cell lines have smaller sized 
nuclei than primary fibroblasts (Figure 3.9 B), further indicating changes associated with can-
cerous transformation. Furthermore, we performed RT-PCR (2.2, 2.9) to show hTERT mRNA 
expression in the immortalized cell lines (Figure 3.9 C).  
These results indicate cell immortalization in common marmoset fibroblasts through hTERT 
transgene expression. However, the generated cell lines do not show the same morphology as 
primary fibroblasts. To our knowledge, no hTERT immortalized common marmoset cell lines 




Figure 3.9. A) Phase contrast images of the hTERT immortalized cell lines and fibroblast controls. P: passage. 
Clone #4 and the polyclonal cell line show a thinner more “needle like” morphology when compared to fibro-
blasts. Fibroblasts in P26 show a flat and broad morphology typical for cells in senescence. Bars = 200µm B) 
hTERT immunofluorescence staining of immortalized cell lines. Immortalized cell lines show expected TERT 
expression (red). No expression was detected in fibroblasts. Bars = 200µm. Only images of clone #4 are shown 
because clone #4 and #1 are indistinguishable from each other C) RT-PCR for expression of hTERT. Primer 
pairs specific for the hTERT transgene were used. As a loading control, β-Actin was amplified. As template 
DNA, cDNA of the immortalized cell lines and fibroblasts was used. Fibroblasts of two different common mar-




The aim of this study was to establish methods for the genomic modification of the common 
marmoset monkey. This would extend the spectrum of possible applications of the common 
marmoset as a model organism in biomedical and preclinical research. The different parts of 
this study were i) the generation of transgenic common marmosets carrying a pluripotency 
specific marker cassette ii) establishing CRISPR/Cas9 system, a new and promising method 
for gene targeting, in common marmoset monkey cells, and iii) generation of immortalized 
common marmoset fibroblast cell lines, and the generation of marmoset iPS cell lines by ro-
bust expression of transgenes from the piggyBac transposon.  
4.1 Generation of EOS-EiP transgenic common marmosets 
To achieve the first aim of this thesis, i.e. in vivo transgenesis of marmoset monkeys, it was 
necessary to learn the required reproductive biology and embryological methods. These 
methods included the oocyte collection (“oocyte-pick up”; OPU), oocyte maturation (“in vitro 
maturation”; IVM), oocyte fertilization (“in vitro fertilization”; IVF) and in vitro culture 
(IVC) of IVF embryos. For all of these methods competence in handling of oocytes and em-
bryos was needed. All the mentioned methods were challenging procedures that needed long-
term training of several months. Therefore, most of the time at the CIEA was needed to ac-
quire and perfect the practical skills to effectively generate transgenic common marmosets. 
The required methods are well established at the CIEA, and proved to ensure highly efficient 
generation of wildtype (Tomioka et al., 2012) and transgenic (Sasaki et al., 2009) common 
marmosets. 
The number of obtained oocytes from animals was dependent on the condition of the animal 
but also on the experience and skill of the operator performing the OPU. To obtain a maxi-
mum number of oocytes at the optimal stage for the IVF, the oocytes were in vitro matured. 
These procedures guaranteed a maximum output of oocytes for IVF. After IVF the embryos 
were injected with the used lentivirus and further cultured in vitro to obtain embryos at the 




In this study the EOS-EiP lentiviral vector was chosen to generate EOS-EiP transgenic com-
mon marmosets. The EOS-EiP cassette was reported to exhibit pluripotency specific eGFP 
expression in mice and human iPSCs (Hotta et al., 2009). As in mice and human such a plu-
ripotency specific eGFP marker system would allow to monitor the developmental state of 
iPS cells. Pluripotency-associated eGFP activity would be a very useful tool study culture 
conditions of iPS cells and to monitor in vivo, i.e. in the embryo, the effects of the activation 
of specific signals transduction pathways with regard to pluripotency. EOS-EiP transgenic 
fibroblasts would also allow the refinement of reprogramming procedures since activation of 
pluripotency could be easily monitored in living cells. In the common marmoset such a mark-
er system was not yet reported. 
We obtained three putatively transgenic marmosets, two of which were proven to carry the 
full EOS-EiP transgene. The animals are kept in the Central Institute for experimental animals 
in Kawasaki, Japan. Germline transmission of the transgene was not confirmed yet. The 
achieved birth rate after embryo transfer (12%) is of an average level for IVF embryos ac-
cording to experiences at the CIEA (Tomioka et al., 2012).  
The EOS-EiP virus injected one-cell stage embryos showed different levels of eGFP expres-
sion after virus injection. Only embryos that showed a clear strong eGFP signal together with 
a timely development were used for embryo transfer into recipient females. A timely devel-
opment of embryos proved to be of great importance to assure proper implantation of embry-
os and thereby to obtain healthy offspring (Sasaki et al., 2009; Tomioka et al., 2012). By us-
ing embryos with a strong eGFP signal, preferably in all blastomeres, the probability of ob-
taining offspring with a strong transgene expression is the highest. Similar eGFP signal inten-
sity in all blastomeres further suggests transgene integration at an early developmental stage. 
Earliest integration of the virus is desired since this leads to less extensive genetic mosaicism 
in the offspring. 
Sasaki et al. (2009) showed germline transmission of the eGFP transgene. As a first step to 
demonstrate germline transmission of the EOS-EiP, sperm samples of the transgenic animal 
I779tgM should be analyzed. At the time this thesis was written the animal I779tgM was most 
likely close to sexual maturity, but no analysis was performed yet at the CIEA (E. Sasaki per-
sonal communication). 
Both living animals (I779tgM, I664tgF) obtained from EOS-EiP injected embryos exhibit 
normal behavior. Furthermore, they do not show any apparent increased susceptibility to dis-
eases compared to wildtype common marmosets. This was also shown for other marmosets 
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derived from non-disease inducing lentivirus-injected embryos (Sasaki et al., 2009) (un-
published data). This is important since theoretically already the random integration of lentivi-
ral vectors can cause harmful genetic changes in embryos and later developmental stages. 
However, if too severe, such mutations prevent proper early development of embryos so that 
they are either eliminated prior to retransfer, or, if retransferred, result in early stage abor-
tions. 
The pluripotency specific activity of the EOS-EiP reporter would mark the pluripotent cell 
fractions (inner cell mass/embryoblast) in preimplantation and early postimplantation embry-
os, allowing live imaging of the different developmental stages. This would help to better 
understand the processes in early embryo development. Furthermore, in cell differentiation for 
preclinical testing of cell replacement therapies, EOS-EiP based GFP expression would mark 
residual pluripotent cells, which harbor a high tumorigenic potential when transplanted. 
In summary, transgenesis in common marmosets offers new possibilities in biomedical re-
search. Genetically modified marmosets can become valuable disease models for translational 
research as well as for efficacy and safety testing of new therapeutics.  
4.2 iPS cell generation from EOS transgenic common marmoset 
fibroblasts using the piggyBac transposon system 
In this study, two iPS cell lines were generated from EOS-EiP transgenic common marmoset 
I780tgM. Both lines were reprogrammed with the classical four factors SOX2, OCT4, KLF4, 
c-MYC (SOKM) using the piggyBac transposon system. The piggyBac transposon construct 
used in this study was designed and constructed by Katharina Debowski (Debowski et al., 
2015). All analyses performed including RT-PCR and IF staining as well as the continuous 
growth and the indistinguishable morphology between the generated iPS cells and the refer-
ence ES cells indicate successful and complete reprogramming. However, additional func-
tional assays like the teratoma formation assay and the emryoid body formation assays would 
be beneficial to prove pluripotency of the iPS cells generated in this study. 
The iPS cells presented in this study were generated with only the classical four (SOKM) re-
programming factors. The cells show the same morphology as common marmoset ES cells 
and are also comparable to published marmoset iPS cells generated with six reprogramming 
factors (SOKMLN) (Debowski et al., 2015; Tomioka et al., 2010). An important difference 
between four factor and six factor reprogramming of marmoset cells shown in this study, is 
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the time necessary for colony formation. The first colonies of four factor reprogrammed cells 
were picked after 91 days. In contrast, six factor reprogrammed cells only needed 28 days 
until first colonies were picked. However, other reports of common marmoset iPS cells gener-
ation with only the classical four factors (Wiedemann et al., 2012; Wu et al., 2010) showed 
different morphologies as observed in this study. The iPS cells published by Wu et al. 2010 
did not exhibit the typical ES/iPS cell characteristics e.g. epitheloid cells forming tightly 
packed cell colonies with a clear colony boundary. Wiedemann et al. 2012 reported iPS cells 
that displayed rather dome-like colony morphology, characteristic for mouse ES cells. The 
differences in methodology between the four factor iPS cells in this study and from Wu and 
Wiedemann are the origin of the reprogramming factors the used method for delivery of re-
programming factors and the time in culture before colony picking/passaging. The repro-
gramming factors used in this study are derived from common marmoset cDNA whereas the 
other groups used human derived reprogramming factors. Wu et al. used retroviral transduc-
tion and cultured the cells for 21 days until colonies were transferred further. Wiedemann et 
al. used a lentiviral vector system for reprogramming factor delivery and cultured the cells for 
12-22 days until colonies were further passaged. Although it is difficult to compare different 
ways of cell reprogramming, the mentioned differences in methodology between the four fac-
tor reprogrammed cells in this study and from Wu et al. and Wiedemann et al. might explain 
the observed differences in iPS cell morphology. Moreover, due to the very limited repro-
gramming period in the Wu and in the Wiedemann studies, it is likely that the cells cultured 
and characterized in these studies were only partly reprogrammed. In our lab mature iPS cell 
lines were never isolated after less than four weeks, even if six factors were used for repro-
gramming. 
The EOS-EiP cassette inserted into the common marmoset genome via lentiviral integration is 
supposed to exhibit pluripotency associated eGFP activity. Hence, it was expected that the 
generated iPS cells show an eGFP signal. However, the cells showed no eGFP activity visible 
in fluorescence microscopy, and flow cytometric analysis was also negative for eGFP expres-
sion. However, RT-PCR results indicate eGFP mRNA expression. Real time quantitative 
PCR, however, detected only very low levels of eGFP mRNA that were only slightly above 
the negative control levels. Therefore, we conclude that eGFP expression is not sufficient for 
eGFP detection through fluorescence microscopy or flow cytometry, but that very low levels 
of eGFP mRNA are produced that are sufficient for RT-PCR detection.  
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Inactivity of eGFP reporter cassette in reprogrammed iPS cells could be due to viral rear-
rangement of the EOS-EiP integration cassette leading to changes in the promoter or eGFP 
sequence. However, sequencing revealed intact sequences for the EOS promoter (early trans-
poson promoter + Sox2/Oct4 enhancer elements) and for the eGFP ORF. 
Hotta and colleagues showed EOS-EiP based eGFP expression in human and mouse iPSCs 
and reported that no viral vector silencing was detected. However, lentiviral vector silencing 
through epigenetic effects (DNA methylation, histone modifications) is a known issue (Anto-
niou et al., 2013; Ellis, 2005) and it is likely that this is the reason for the inactivity of the 
EOS-EiP cassette in common marmoset iPS cells. However, this has to proven by appropriate 
methods like DNA methylation analysis.  
Hotta and colleagues used an early transposon promoter that was shown to be highly active in 
mouse and human pluripotent cells but inactive in differentiated cells. (Maksakova and Mag-
er, 2005). This promoter, as well as the Sox2 and Oct-4 enhancers in the EOS-EiP vector, 
were all derived from mouse DNA. Even though the EOS-EiP reporter worked in human 
cells, the mouse origin could also influence the activity of the construct in marmoset cells. 
If common marmoset iPS cells with EOS-EiP activity can be obtained, they would be a valu-
able system for investigating cell reprogramming and cell differentiation. In reprogramming 
experiments developing pluripotent colonies would be marked by GFP fluorescence before a 
selection through colony morphology would be possible. This would allow investigating the 
earliest stages of reprogramming helping to better understand the underlying mechanisms of 
cell reprogramming. Furthermore, EOS-EiP would be beneficial for preclinical testing of cell 
replacement therapies. Since differentiation of iPS cells would cause GFP silencing, GFP ex-
pression would mark residual pluripotent cells. This would assure that only properly differen-
tiated cells are used for cell transplantation but at the same time also that residual pluripotent 
cells, which harbor a high tumorigenic potential when transplanted, could be eliminated. 
The piggyBac based reprogramming system used in this study is reversible, i.e. the integrated 
reprogramming cassette can be excised (Kim and Pyykko, 2011). Therefore, using the piggy-
Bac system, it is possible to obtain transgene free iPS cells. This reduces the risk of tumor-
igenicity because no exogenous genes remain randomly integrated in the cell genome. Fur-
thermore, it is especially desirable to obtain c-MYC transgene free iPS cells because c-MYC is 
a proto-oncogene and its overexpression can result in tumor formation. Other advantages of 
the piggyBac system include that no silencing has been reported yet and that larger transgenes 
can be transferred then for instance by lentiviruses.  
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Induced PS cells have great potential in the search for new treatments for cell and tissue de-
generative diseases, e.g. Parkinson’s disease (PD). Induced PS cell-derived cells and tissues 
could be used for tissue or cell replacement therapies. For the development of such therapies 
it is crucial to perform efficacy and safety testings of the highest standard possible. Non-
human primate (NHP) iPS cells and NHP themselves are of immense value for such testings 
because of their genetical, developmental, behavioral and physiological comparability to hu-
mans (t Hart et al., 2015). Furthermore, due to their long life span, NHP allow safety testings 
over longer periods which might be especially valuable in progressive diseases like PD. 
Therefore efficacy and safety testing in NHP are of very high translational value (Belmonte et 
al., 2015; t Hart et al., 2015). 
4.3 Targeting the LRRK2 gene of the common marmoset using 
the CRISPR/Cas9 system 
In this part of the study I applied the CRISPR/Cas9 system to modify common marmoset 
monkey cells. Generation of gene-targeted common marmoset cells and animals may have a 
big impact on future biomedical research allowing generation of transgene free genetic dis-
ease models. 
The CRISPR/Cas9 experiments performed in this study caused NHEJ based gene knockouts 
in marmoset cells. Preliminary work for this study also showed activity of CRISPR/Cas9 in 
marmoset fibroblasts for other genes (data not shown). The generation of fibroblasts carrying 
the LRRK2 Gly2019Ser pointmutation by CRISPR/Cas9 induced HDR was not successful 
although overall 576 clones from four different experiments were checked. Other experiments 
with CRISPR/Cas9 in common marmoset cells, performed by scientists at the CIEA, were 
also unsuccessful in obtaining cells with HDR mediated gene modification (unpublished da-
ta). This additionally indicates the difficulty of CRISPR/Cas9 mediated HDR based targeted 
gene modification in the common marmoset.  
Even though some groups reported successful CRISPR/Cas9 mediated HDR in other mamma-
lian species (Wang et al., 2013; Zhu et al., 2015), others report only partial, or no integration 
of a homologous template (Whitworth et al., 2014). However, successful HDR only show 
very low efficiencies.  
Several approaches to increase CRISPR/Cas9 based HDR are known. Reports showed that 
modified Cas9 nuclease, active as nickase with paired gRNAs, can lead to higher HDR effi-
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ciency (Mali et al., 2013a; Rong et al., 2014). In this altered CRISPR/Cas9 system the Cas9 
nuclease only nicks a single strand of the DNA. Therefore, two gRNAs, one for the leading 
strand and one for the lagging strand, are necessary to achieve a doublestrand break. This fur-
ther reduces the possibility of off-target effects because proximity of both gRNAs is necessary 
to induce a double strand break. In Drosophila melanogaster, it was recently shown that 
knockout or knockdown of the DNA Ligase4 (Lig4) gene highly increases the occurrence of 
CRISPR/Cas9 based HDR events (Böttcher et al., 2014; Gratz et al., 2014). The DNA Lig-
ase4 joins double-strand breaks during NHEJ. Knockout or knockdown of Lig4 subsequently 
results in a repression of the NHEJ pathway and in an increase in HDR events. In human 
cells, a recent report (Ho et al., 2015) showed successful knockdown of LIG4 via RNAi with 
subsequent increase of HDR events. An alternative to LIG4 as target to increase HDR is the 
DNA-dependent protein kinase catalytic subunit (DNA-PKcs). Pharmacological inhibitors of 
DNA-PKcs were reported to repress the NHEJ pathway, thereby increasing the occurrence of 
HDR events (Robert et al., 2015) Both, Lig4 and DNA-PKcs based NHEJ repression might 
allow successful HDR also in other species. In future experiments the application of these 
refined strategies should be tested in marmoset cells. 
Possible off-target effects of the CRISPR/Cas9 system are well documented (Fu et al., 2013; 
Hsu et al., 2013; Pattanayak et al., 2013). However, in this study the main aim was to achieve 
modification of the target site in the common marmoset. Therefore, possible off-targets were 
not analyzed. Though, the used gRNAs were selected using the CRISPR design tool 
(http://crispr.mit.edu/), operated by the Zhang lab. This online tool analyses the gRNAs for 
possible off-target effects through cross-referencing with the target genome, thereby minimal-
izing the likelihood of off-target activity. However, the used gRNAs were only cross-
referenced with the human genome, since the common marmoset genome is not available in 
the CRISPR design tool yet. For future applications of the CRISPR/Cas9 system, analyzing 
possible off-target loci is of great importance to rule out off-target mutations. 
Liang et al. (2015) reported CRISPR/Cas9 based gene modification in human tripronuclear 
embryos. Even though the embryos were not viable (because of triploidy) the study was high-
ly controversial. Even though the experiments are highly controversial and ethically discussi-
ble, the theoretical potential of the CRISPR/Cas9 technology for the treatment of human dis-
eases is indisputable. However, a major obstacle for the application of CRISPR/Cas9 in hu-
man embryo found in that study was the occurrence of mutations at several off-target loca-
tions. A NHP model like the common marmoset would be helpful for further testing and “fi-
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ne-tuning” of CRISPR/Cas9 before it should be further used in human embryos or cells des-
ignated for future cell replacement therapy. 
I was able to show that CRISPR/Cas9 allows efficient gene knockout in common marmoset 
cells. This will allow generation of in vitro and in vivo common marmoset diseases models in 
the future. For the introduction of point mutations or additional DNA sequences, the system 
needs to be further refined.  
4.4 piggyBac-mediated expression of hTERT resulted in 
immortalization of common marmoset fibroblasts 
In this study three immortalized fibroblast cell lines were generated by piggyBac mediated 
expression of hTERT. Two of the generated cell lines were derived from a single cell and are 
therefore defined as monoclonal cell lines. 
The high proliferation potential of the generated cell lines in comparison to control cells indi-
cates successful immortalization. However, the slight changes in morphology also suggest a 
change in gene expression that results from stable hTERT expression.  
Several studies report similar changes in cell morphology (Mondello et al., 2003; Toouli et 
al., 2002; Wang et al., 2000; Zongaro et al., 2005) while others report a wildtype phenotype 
and no further changes in hTERT immortalized cells (Bodnar et al., 1998; Morales et al., 
1999; Simonsen et al., 2002). If the observed morphological changes result from hTERT ex-
pression or the random piggyBac transposon induced integration cannot be determined. The 
changed cell morphology of the immortalized cells in this study compared to primary fibro-
blasts could indicate cancer associated changes in gene expression (Belgiovine et al., 2008; 
Zongaro et al., 2005). Further analysis of the cells is necessary to determine possible cancer 
associated changes. Therefore, a transcriptome analysis of the immortalized cells and control 
cells will be performed to check for differences in gene expression of cancer associated genes 
like tumor protein p53 (p53) or retinoblastoma (RB). However, the obtained immortalized cell 
lines allow long-term studies with at least fibroblast like cells under a constant cellular pheno-
type. This offers new possibilities for research with these cells that are not possible with pri-
mary cells with a limited lifetime. An advantage of monoclonal cell lines is that they offer the 
possibility to perform analysis multiple times under genetically and phenotypically identical 
conditions. Moreover, stable marmoset cell lines could be useful for the development of bio-
logics, e.g. cytokines, monoclonal antibodies. 
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An alternative to immortalization with hTERT is the use of the viral oncogene simian virus 40 
large T antigen (SV40T). It was shown that SV40T is sufficient to immortalize rodent cells 
(Allen et al., 2000), but in human cells it is only sufficient to overcome senescence but not 
crisis. Furthermore, SV40T treated cells generally exhibit more severe changes in morphology 
and gene expression than hTERT treated cells when compared to wildtype cells. However, 
some studies showed that hTERT expression is not always sufficient to achieve cell immortal-
ization (Darimont et al., 2002; Kiyono et al., 1998; Yudoh et al., 2001). Especially in immor-
talization-refractory cell types, e.g. adult hepatocytes or respiratory tract epithelial cells, 
hTERT alone is not always sufficient to stably immortalize cells (Lundberg et al., 2002; Ram-
boer et al., 2014). However, the combined expression of hTERT and other factors like SV40 
Tag was shown to successfully immortalize such cell types (Nguyen et al., 2005)(Kemp et al., 
2008). Human TERT based immortalization of differentiated cell types could be used to gen-
erate cellular in vitro models. Examples of possible candidate cell types of the respiratory 
epithelium and hepatocytes. As mentioned above, such cells would most likely require a 
combined expression of hTERT and SV40T. However, marmoset or other NHP in vitro mod-
els of e.g. the respiratory epithelium or the liver could be used to investigate infectious diseas-
es and to test new drugs for such diseases. The advantage of such immortalized cells in com-
parison to primary cells or tissue culture would be the reproducibility of such experiments 
under genetically and phenotypically defined conditions. Furthermore, such immortalized in 
vitro models would reduce the need for primary cells and tissues, thereby reducing the num-
ber of animals needed for cell and tissue collection. 
4.5 Summary 
I was able to successfully perform transgenesis and gene modification in the common marmo-
set on the cellular and organismic level. 
I generated two transgenic common marmoset monkeys carrying the EOS-EiP transgene us-
ing lentiviral transduction. Furthermore, I was able to generate two iPS cell lines from prima-
ry fibroblasts of the EOS-EiP transgenic marmosets using the virus-free piggyBac transposon 
system. Notably, I succeeded in reprogramming the fibroblasts making use of only the four 
classical reprogramming factors SOX2, OCT4, KLF4 and c-MYC, omitting LIN28, which 
was reported to be essential for common marmoset monkey cell reprogramming. However, 
refinement is necessary to achieve the initial goal of obtaining cells with an active pluripoten-
cy reporter. I also successfully applied the CRISPR/Cas9 system to modify the Parkinson’s 
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disease associated gene LRRK2 in common marmoset primary fibroblasts. However, to 
achieve CRISPR/Cas9 induced homology directed repair (HDR) further research is necessary. 
Additionally, I generated immortalized common marmoset monkey fibroblast cell lines by 
stably introducing the hTERT transgene, using the piggyBac transposon system. 
Overall, the achievements in this study hopefully contribute to an expanded application of the 
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